[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"interventionName\":\"Surgery\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":679},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,103,0,25,[9,41,74,101,131,157,181,211,232,260,287,315,344,374,396,419,439,473,499,528,554,583,609,637,658],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100054214","predicting-early-tumor-recurrence-in-patients-with-esophageal-squamous-cell-carcinoma-100054214",false,"NCT06476067","Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma","Predicting Postoperative Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Patients who had histologically confirmed ESCC.\n2. Patients who had undergone only complete esophagectomy with radical lymph node dissection without chemotherapy or radiotherapy before or after surgery.\n3. Patients for whom tissue samples are available\n4. Patients who were followed-up completely, with information on observation periods of at least 2 years after surgery.\n5. Written informed consent following full study information is provided to the patient.\n\nExclusion Criteria:\n\n1. Patients lacking clinical information within 2 years of surgery.\n2. Patients with multiple cancers.","ALL","20 Years",{"count":20,"type":21},150,"ESTIMATED","OBSERVATIONAL","The prognosis of patients with esophageal squamous cell carcinoma (ESCC) who develop post-operative early tumor recurrence is often relatively poor. Therefore, biomarker that can detect micro metastases before the start of treatment is required. Epigenomic alterations such as DNA methylation have attracted attention as promising biomarkers. The investigators aim to predict early recurrence based on whole genome DNA methylation analysis of esophageal cancer.",[25,26,27],"Esophageal Cancer","Recurrence","DNA Methylation","RECRUITING","2026-07-10",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2006-01-01",{"date":36,"type":21},"2028-06-18",{"name":38,"class":39},"City of Hope Medical Center","OTHER",2,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100643980","phase-3-apg-157-in-locally-advanced-head-and-neck-squamous-cell-carcinoma-100643980","NCT07667296","APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma","A Multicenter, Randomized, Open-Label Phase 3 Study of APG-157 as Neoadjuvant Therapy or as Induction and Maintenance Therapy in Locally Advanced Head and Neck Squamous Cell Carcinoma","Inclusion Criteria\n\nCohort A (Resectable Disease)\n\n1. Adults ≥18 years\n2. Histologically or cytologically confirmed, previously untreated locally advanced head and neck squamous cell carcinoma (LA-HNSCC) of the oral cavity or oropharynx.\n3. Resectable disease appropriate for curative-intent surgery.\n4. Stage III-IVA disease according to AJCC criteria:\n\n   * Oropharynx, p16-positive: Stage III (T4, N0-N3, M0)\n   * Oropharynx, p16-negative: Stage III or IVa (T3-T4, N0-N2, M0)\n   * Oral cavity: Stage III or IVa (T3-T4, N0-N2, M0)\n5. Objectively medically ineligible for perioperative pembrolizumab according to protocol-defined objective criteria.\n6. HPV\u002Fp16 testing available for stratification.\n7. Measurable or evaluable disease.\n8. Life expectancy ≥12 months.\n9. ECOG Performance Status ≤2.\n10. Negative pregnancy test for women of childbearing potential and agreement to use effective contraception.\n11. Ability to comply with study procedures.\n\nCohort B (Unresectable \u002F Medically Inoperable Disease)\n\n1. Adults ≥18 years\n2. Histologically or cytologically confirmed, previously untreated LA-HNSCC of the oropharynx. Disease not suitable for curative-intent surgery.\n3. Stage III-IVA disease according to AJCC criteria:\n\n   * p16-positive Stage III (T4, N0-N3, M0) with \\>10 pack-year smoking history\n   * p16-negative Stage III or IVa (T3-T4, N0-N2, M0)\n4. HPV\u002Fp16 testing available for stratification.\n5. Presence of evaluable tumor burden.\n6. Eligible to receive definitive chemoradiotherapy.\n7. Life expectancy ≥12 months.\n8. ECOG Performance Status ≤2.\n9. Adequate organ function.\n10. Contraception requirements met.\n11. Ability to comply with study procedures.\n\nExclusion Criteria\n\nCohort A Specific:\n\n* Stage I-II disease\n* Stage IVb or Ivc disease\n* T4b unresectable disease\n* N3 disease where applicable\n* Medically eligible for perioperative pembrolizumab\n\nCohort B Specific:\n\n* Stage I-II disease\n* Disease not appropriate for curative-intent CRT\n* Active autoimmune disease requiring systemic therapy\n* Prior solid organ or allogeneic stem cell transplant\n* Ongoing immunosuppression \\>10 mg\u002Fday prednisone equivalent\n\nCommon Exclusion Criteria:\n\n* Primary tumor arising from the nasopharynx, hypopharynx, larynx, paranasal sinus, or unknown primary site.\n* Prior treatment for current head and neck squamous cell carcinoma.\n* Prior malignancy unless protocol exceptions met\n* Distant metastatic disease\n* Live vaccine within 30 days\n* Known hypersensitivity to APG-157 or its components.\n* Unresolved clinically significant toxicity\n* Recent participation in another investigational study\n* Active uncontrolled infection\n* Significant uncontrolled cardiovascular disease\n* Pregnancy or breastfeeding.\n* QTcF \\>500 msec or congenital long QT syndrome\n* Any condition compromising safety, compliance, or study interpretation\n\nRandomization ratio: 1:1 within each cohort\n\nStratification Factors:\n\nCohort A:\n\n* HPV\u002Fp16 status,\n* Planned platinum strategy,\n* PD-L1 CPS category\n\nCohort B:\n\n* HPV\u002Fp16 status\n* Planned platinum strategy\n* Geographic region.","18 Years",{"count":50,"type":21},826,"INTERVENTIONAL",[53],"PHASE3","This Phase 3, multicenter, randomized, open-label study evaluates APG-157 in adults with newly diagnosed locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Two independently powered cohorts are enrolled based on treatment pathway. Cohort A evaluates APG-157 administered as neoadjuvant therapy before curative-intent surgery in participants with resectable oral cavity or oropharyngeal cancer who are medically ineligible for perioperative pembrolizumab. Cohort B evaluates APG-157 administered as induction therapy before definitive chemoradiotherapy and as maintenance therapy after chemoradiotherapy in participants with unresectable or medically inoperable disease. Participants are randomized 1:1 within each cohort to receive APG-157-based treatment or standard-of-care therapy. The primary hypothesis is that APG-157 given before definitive surgery followed by (chemo)radiotherapy improves event-free survival (EFS) compared to surgery and adjuvant (chemo)radiotherapy alone (Cohort A), and that APG-157 given as induction therapy prior to definitive chemoradiotherapy (CRT) followed by maintenance APG-157 improves EFS compared to definitive CRT alone (Cohort B).",[56,57,58,59,60,61,62],"Head and Neck Cancer","Head and Neck (HNSCC)","Oropharyngeal","Oral Cavity","Oral Cavity Carcinoma","Oropharynx Squamous Cell Carcinoma","Oral Cavity Squamous Cell Carcinoma","NOT_YET_RECRUITING","2026-06-29",{"date":66,"type":32},"2026-07-01",{"date":68,"type":21},"2026-07",{"date":70,"type":21},"2032-12",{"name":72,"class":73},"Aveta Biomics, Inc.","INDUSTRY",{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":81,"minAge":48,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":51,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":40},"100586366","phase-2-neoadjuvant-sbrt-followed-by-nab-paclitaxel-combined-with-toripalimab-in-hrher2--breast-cancer-100586366","NCT06914440","Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+\u002FHER2- Breast Cancer","Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+\u002FHER2- Breast Cancer: A Single-arm, Prospective Clinical Trial","Inclusion Criteria:\n\n1. Female patients aged ≥18 and ≤75 years at the time of signing informed consent.\n2. ECOG PS status of 0-1.\n3. Breast cancer assessed as non-metastatic (M0), meeting all of the following:\n\n   1. Clinical stage: Stage IIB, IIIA, IIIB, or IIIC\n   2. Required imaging assessments (within 28 days): Abdominal CT, ECT Bone scan, Chest CT and Brain MRI\n4. Histologically or pathologically confirmed invasive carcinoma of no special type, with all of the following:\n\n   1. Grade 2 or 3 (confirmed by central laboratory);\n   2. ER-positive (\\>1% staining) and\u002For PR-positive (\\>1% staining) by IHC;\n   3. HER2-negative (IHC 0\u002F1+ or HER2\u002Fneu FISH ratio ≤1.8);\n   4. Ki-67 ≥15%.\n5. Patient deemed eligible for radiotherapy after MDT evaluation.\n6. No prior antitumor therapy within 1 month before enrollment.\n7. Organ Function Requirements (within 7 days prior to enrollment):\n\n   1. Complete blood count (no transfusion or hematopoietic growth factors within 7 days): ANC ≥1.5×10⁹\u002FL; ALC ≥0.5×10⁹\u002FL; Platelets ≥100×10⁹\u002FL; Hemoglobin ≥90 g\u002FL; WBC ≥3.0×10⁹\u002FL and ≤15×10⁹\u002FL;\n   2. Blood biochemistry (no transfusion\u002Falbumin within 7 days): ALT\u002FAST ≤2.5×ULN; ALP ≤2.5×ULN；BUN\u002FCr ≤1.5×ULN; Cr≥60 mL\u002Fmin (Cockcroft-Gault formula);\n   3. Coagulation: PT\u002FAPTT ≤1.5×ULN; INR ≤1.5×ULN (if no anticoagulant therapy);\n   4. Urinalysis: Urine protein \\\u003C2+; if ≥2+, 24-hour urine protein must be ≤1g;\n   5. Thyroid function:TSH ≤1×ULN; if abnormal, normal T3\u002FT4 levels required for eligibility.\n8. Women of childbearing potential must:\n\n   1. Have a negative serum pregnancy test within 7 days before treatment;\n   2. Use highly effective contraception during the study and for 180 days after the last dose.\n9. Voluntarily sign informed consent, demonstrate good compliance, and commit to follow-up.\n\nExclusion Criteria:\n\n1. Inflammatory Breast Cancer.\n2. Comorbidities\u002FMedical History:\n\n   1. Autoimmune disease: patients with any known or suspected autoimmune disease, except: hypothyroidism due to autoimmune thyroiditis managed with hormone replacement therapy only, stable type-1 diabetes with well-controlled blood glucose.\n   2. Cardiovascular Diseases: poorly controlled hypertension despite medication (SBP \\>140 mmHg or DBP\\>90 mmHg). And with the history (within 6 months prior to enrollment) of myocardial infarction, severe\u002Funstable angina, NYHA Class ≥2 heart failure, clinically significant arrhythmias as well as symptomatic congestive heart failure.\n   3. Interstitial lung disease, non-infectious pneumonitis, or other uncontrolled systemic diseases (e.g., diabetes, pulmonary fibrosis, acute pneumonia);\n   4. Vaccination: receipt of live attenuated vaccines within 28 days prior to enrollment or planned during the study;\n   5. Infections: HIV\u002FAIDS, active hepatitis(HBV-DNA ≥500 IU\u002FmL; HCV-RNA above detection limit), or co-infection with HBV and HCV, severe infections within 4 weeks prior to enrollment (e.g., bacteremia, severe pneumonia requiring hospitalization), active infection requiring systemic antibiotics (CTCAE≥Grade 2) within 2 weeks prior to treatment, active tuberculosis within 1 year prior to enrollment;\n   6. Unexplained fever \\>38.5°C during screening (unless deemed tumor-related by the investigator);\n   7. Malignancy History: other malignancies diagnosed within 5 years prior to enrollment (except adequately treated basal cell carcinoma, squamous cell skin cancer, or cervical carcinoma in situ);\n   8. Surgery:Major surgery within 28 days prior to enrollment (diagnostic biopsies or PICC line placement are allowed);\n   9. Transplant: Prior or planned allogeneic bone marrow or solid organ transplant;\n   10. Neurological: peripheral neuropathy ≥Grade 2;\n   11. Gastrointestinal: clinically significant bowel obstruction;\n   12. Thrombotic Events: arterial\u002Fvenous thrombosis within 6 months prior to enrollment (e.g., stroke, transient ischemic attack, DVT, pulmonary embolism);\n   13. Bleeding Risk: hemoptysis (≥2.5 mL\u002Fday) within 2 months prior to enrollment, clinically significant bleeding within 3 months prior to enrollment (e.g. gastrointestinal bleeding, hemorrhagic gastric ulcer, baseline fecal occult blood≥++), and the known bleeding\u002Fthrombotic disorders (e.g., hemophilia, coagulopathy, thrombocytopenia, hypersplenism);\n   14. Coagulation abnormalities (INR \\>1.5×ULN or APTT \\>1.5×ULN), or requiring long-term anticoagulation (warfarin\u002Fheparin) or antiplatelet therapy (aspirin≥300 mg\u002Fday or clopidogrel ≥75 mg\u002Fday).\n3. Treatment-Related Exclusions:\n\n   1. Prior systemic targeted therapy or immunostimulants (e.g., interferon, IL-2) within 4 weeks before treatment;\n   2. Known allergy to the investigational drug (recombinant humanized anti-PD-1 mAb) or its excipients.\n4. Clinical Trial Participation: participation in another drug trial within 4 weeks prior to enrollment, or within 5 half-lives of the last investigational drug dose.\n5. Substance Abuse: history of drug\u002Falcohol abuse or dependency.\n6. Pregnancy\u002FLactation: pregnant, breastfeeding, or planning pregnancy during the study.\n7. Investigator' s Discretion: other conditions that may compromise subject safety or study integrity (e.g., severe lab abnormalities, social factors).","FEMALE","75 Years",{"count":84,"type":21},27,[86],"PHASE2","The goal of this clinical trial is to evaluate the efficacy and safety of neoadjuvant radiotherapy followed by chemotherapy combined with immunotherapy in patients with previously untreated stage IIB-IIIC (cT3N0 or cT2-4N1-3) HR-positive and HER2-negative breast cancer. 27 enrolled patients will be assigned to receive stereotactic body radiotherapy followed by Nab-Paclitaxel combined with Toripalimab. The main question it aims th answer is that whether the combination therapy of radiotherapy, de-escalated chemotherapy, and immunotherapy could improve the pCR rate of HR-positive and HER2-negative breast cancer.",[89],"Breast Cancer",[89,91],"Neoadjuvant therapy","2026-06-21",{"date":94,"type":32},"2026-06-23",{"date":96,"type":32},"2025-06-05",{"date":98,"type":21},"2030-12",{"name":100,"class":39},"Xijing Hospital",{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":82,"enrollmentInfo":109,"targetDuration":4,"studyType":51,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100619043","phase-2-intestinal-low-dose-radiotherapy-plus-immunochemotherapy-for-conversion-of-borderline-resectableunresectable-esophageal-squamous-cell-carcinoma-100619043","NCT07339488","Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable\u002FUnresectable Esophageal Squamous Cell Carcinoma","Efficacy and Safety of Combining Intestinal Low Dose Radiotherapy Plus Tislelizumab and Chemotherapy for Conversion of Borderline Resectable\u002FUnresectable Esophageal Squamous Cell Carcinoma","ILDR-03","Inclusion Criteria:\n\n1. Patients voluntarily enroll in this study, sign an informed consent form, and demonstrate good compliance.\n2. Age ≥18 years and ≤75 years; both sexes are eligible.\n3. ECOG performance status score of 0-1.\n4. Pathologically confirmed esophageal squamous cell carcinoma (ESCC) prior to surgery.\n5. Thoracic esophageal cancer.\n6. Unresectable lesions, defined as: T4 stage; marginally resectable T3 stage (invading other organs, e.g., trachea, bronchus, or aorta not ruled out by imaging); presence or absence of unresectable lymph nodes or metastatic lymph nodes invading adjacent organs; presence or absence of supraclavicular lymph node metastasis; or clinically confirmed unresectable disease by the surgeon.\n7. No prior history of anti-tumor treatment, including chemotherapy, hormonal therapy, radiotherapy, or immunotherapy.\n8. Baseline laboratory requirements (within 7 days prior to enrollment):\n\n   Hematology:\n   1. Hb≥90 g\u002FL (no transfusion within 14 days)\n   2. NEUT ≥1.5×10⁹\u002FL\n   3. PLT ≥100×10⁹\u002FL\n   4. WBC≥3×10⁹\u002FL\n\n   Biochemistry:\n   1. ALT and AST≤2.5×ULN\n   2. TBIL≤1.5×ULN\n   3. SCr≤1.5×ULN; or CrCl≥60 mL\u002Fmin Coagulation: APTT, INR, and PT≤1.5×ULN Thyroid function: TSH≤ULN (if abnormal, FT3\u002FFT4 levels should also be considered; eligible if FT3\u002FFT4 are normal) Echocardiography: LVEF≥50%\n9. Female subjects need to agree to use contraception during the study and for 6 months post-study; serum pregnancy test negative within 7 days prior to enrollment; non-lactating. Male subjects must agree to use contraception during the study and for 6 months post-study.\n10. No psychological, familial, social, or geographical factors that may impair protocol adherence.\n11. Other parameters meet general clinical trial enrollment criteria.\n12. The subject or authorized representative has read, fully understands the patient information sheet, and signed the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with distant metastases other than supraclavicular lymph node metastases.\n2. Presence or high risk of esophageal perforation.\n3. Patients with contraindications to radiotherapy or immune checkpoint inhibitor (ICI) therapy.\n4. Patients who previously experienced unacceptable toxicity after receiving ICI therapy.\n5. Patients with a history of thoracoabdominal\u002Fpelvic radiotherapy within 6 months prior to enrollment.\n6. Adverse reactions from prior anti-tumor treatment have not recovered to CTCAE v5.0 grade≤1 (excluding toxicities deemed by the investigator to pose no safety risk, such as fatigue or alopecia).\n7. Subjects with active, uncontrolled systemic bacterial, viral, or fungal infections despite optimal treatment.\n8. Respiratory depression, airway obstruction, or tissue hypoxia.\n9. Severe cardiac disease (i.e., NYHA functional class II or higher).\n10. Markedly abnormal liver or kidney function (i.e., indicators \\>3 times the upper limit of normal).\n11. Active hepatitis B, hepatitis C, HIV, or syphilis.\n12. Active brain disease or central nervous system\u002Fmeningeal metastases with significant symptoms, or impaired decision-making capacity.\n13. Hypersensitivity to drugs included in the trial.\n14. Drug and\u002For alcohol abuse.\n15. Pregnant or lactating women.\n16. Concurrent participation in another therapeutic clinical trial.\n17. Major surgical procedure within 30 days prior to enrollment.\n18. Use of antibiotics, antifungals, antivirals, or antiparasitics within 4 weeks prior to registration.",{"count":110,"type":21},43,[86],"Esophageal cancer (EC) ranks among the leading malignant gastrointestinal tumors globally in terms of both incidence and mortality. Cases of EC in China account for over 50% of the global total, with squamous cell carcinoma being the primary pathological type. Locally advanced EC (LAEC), particularly cases where radical surgical resection is not feasible, exhibits high recurrence rates and low 5-year survival rates. However, studies have shown that patients with LAEC who undergo comprehensive treatment followed by surgery experience significantly prolonged survival and improved quality of life compared to those who do not receive surgical intervention.\n\nCurrent conversion treatment regimens under investigation include: chemotherapy alone, chemoradiotherapy, immunotherapy combined with chemotherapy, and immunotherapy combined with chemoradiotherapy-each of these approaches has distinct advantages and limitations. Immunochemotherapy has emerged as a current research focus: it not only demonstrates significantly superior efficacy compared to chemotherapy alone but also exhibits lower cumulative toxicity than radiotherapy-combined conversion regimens, resulting in a more favorable overall benefit-risk ratio. As such, it represents the most promising conversion treatment strategy.\n\nRetrospective and prospective clinical studies have shown that low-dose radiotherapy targeting the small intestine can enhance the anti-tumor response of immune checkpoint inhibitors (ICIs) in patients with advanced solid tumor, prolong their overall survival, and increase the incidence of the abscopal effect. Further mechanistic investigations have revealed that intestinal low-dose radiotherapy (ILDR) may augment the immune cancerous lethality by modulating the gut microbiota and their metabolic profiles.\n\nBased on the findings from these preliminary studies, the current research plans to conduct a prospective phase II single-arm clinical trial to investigate the efficacy and safety of ILDR combined with immunochemotherapy as conversion therapy in patients with borderline resectable or unresectable esophageal squamous cell carcinoma (BR\u002FUR ESCC). This research plans to enroll at least 39 evaluable cases or a total of 43 cases in two seperated stages, focusing on patients with thoracic BR\u002FUR ESCC. Patients will receive a single fraction of ILDR with a mean dose of 1 Gy, concurrently with 3 cycles of albumin-bound paclitaxel (260 mg\u002Fm² on day 1), cisplatin (75 mg\u002Fm² on day 1), and tislelizumab (200 mg on day 1). The efficacy and safety of the treatment will be evaluated throughout the study.",[114,115,116,117,118,119,120],"Borderline Resectable Carcinoma","Unresectable Cancer","Esophageal Squamous Cell Carcinoma (ESCC)","Immune Checkpoint Inhibitor","Chemotherapy","Radiotherapy","Tislelizumab","2026-06-17",{"date":123,"type":32},"2026-06-18",{"date":125,"type":32},"2025-12-05",{"date":127,"type":21},"2028-11-01",{"name":129,"class":39},"Chuangzhen Chen",1,{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100642073","surgery-plus-postoperative-radiotherapy-for-t4-sinonasal-adenoid-cystic-carcinoma-a-prospective-observational-study-100642073","NCT07652489","Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma: A Prospective Observational Study","SPORT-SNACC: A Prospective, Multicenter, Observational Cohort Study of Surgery Plus Postoperative Radiotherapy in T4 Sinonasal Adenoid Cystic Carcinoma","SPORT-SNACC","Inclusion Criteria:\n\n1. Age 18 80 years, any gender; ECOG performance status 0 2; life expectancy ≥6 months.\n2. Histologically confirmed primary sinonasal adenoid cystic carcinoma (cribriform, tubular, solid, or mixed type). Other malignancies excluded.\n3. T4 stage (T4a or T4b) according to AJCC 8th edition, based on contrast enhanced MRI\u002FCT.\n4. N0 2 (operable lymph node metastasis allowed).\n5. M0 (no distant metastasis on chest CT and abdominal ultrasound) OR M1 with stable limited lung metastases; (c) stable on two CT scans ≥3 months apart; (d) no respiratory symptoms.\n6. Previously untreated (no radiotherapy, chemotherapy, targeted therapy, immunotherapy, or tumor resection). MDT deems technically resectable (R0\u002FR1 achievable, not diffusely unresectable).\n7. Adequate organ function within 14 days before enrollment: ANC ≥1.5×10⁹\u002FL, platelets ≥100×10⁹\u002FL, Hb ≥90 g\u002FL; ALT\u002FAST ≤2.5×ULN, TBil ≤1.5×ULN, Cr ≤1.5×ULN or CrCl ≥50 mL\u002Fmin; LVEF ≥50%, no uncontrolled arrhythmia.\n8. Willing and able to provide written informed consent for clinical data collection (and optional biospecimen banking). Investigator judges good compliance.\n\nExclusion Criteria:\n\n1. Progressive lung metastases within 6 months (new lesions or \\>20% increase); extrapulmonary metastases (liver, bone, brain); symptomatic lung metastases.\n2. MDT judged unresectable, e.g., bilateral cavernous sinus invasion, brain parenchyma invasion, bilateral internal carotid artery encasement.\n3. Primary tumor outside sinonasal cavity (e.g., major salivary glands, oropharynx); non ACC histology.\n4. Other active malignancy within 5 years (except cured basal cell carcinoma, cervical carcinoma in situ, etc.).\n5. Severe comorbidities: NYHA class III\u002FIV heart failure, recent myocardial infarction or unstable angina, uncontrolled hypertension (≥160\u002F100 mmHg); COPD requiring home oxygen or interstitial lung disease; decompensated cirrhosis; active hepatitis B\u002FC without antiviral therapy; nephropathy requiring dialysis; active serious infection; active bleeding or coagulopathy (INR \\>1.5×ULN without anticoagulation, or platelets \\\u003C50×10⁹\u002FL).\n6. Special populations: pregnant or breastfeeding; unwilling to use contraception (if childbearing potential); severe allergy to medications required for surgery\u002Fradiotherapy; severe psychiatric or cognitive disorder impairing cooperation; currently participating in another interventional trial.\n7. Unable to undergo contrast enhanced MRI (metal implants, claustrophobia, gadolinium allergy); investigator judges inability to complete follow up (e.g., living abroad, substance abuse).","80 Years",{"count":141,"type":21},70,"This observational study follows patients with T4 stage sinonasal adenoid cystic carcinoma (a rare cancer of the nasal cavity\u002Fsinuses) who receive standard treatment: surgery followed by postoperative radiotherapy. The main goal is to measure the 3-year progression-free survival rate (the percentage of patients alive without cancer growth or spread). We will also assess overall survival, recurrence, side effects, and quality of life. This multicenter, prospective study will provide much-needed real-world data to improve patient counseling and guide future research.",[144,145],"Adenoid Cystic Carcinoma","Sinonasal Carcinoma",[147],"Carcinoma, Adenoid Cystic, Sinonasal, Radiotherapy, Adjuvant, Prospective Studies, Observational Study, Progression-Free Survival","2026-06-12",{"date":121,"type":32},{"date":151,"type":21},"2026-06-01",{"date":153,"type":21},"2031-06-01",{"name":155,"class":39},"Eye & ENT Hospital of Fudan University",6,{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":82,"enrollmentInfo":164,"targetDuration":4,"studyType":51,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":130},"100599800","phase-2-tislelizumab-combined-with-anlotinib-and-nab-paclitaxel-in-iii-resectable-non-small-cell-lung-cancer--a-prospective-single-arm-phase-ii-study-100599800","NCT07089199","Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study","TitAN","Inclusion Criteria:\n\n1. Age 18-75 years old, gender is not limited;\n2. Histologically confirmed Stage III non-small cell lung cancer (AJCC Stage 8th edition)\n3. The tumor is resectable after assessment by the attending surgeon\n4. EGFR\u002FALK mutation negative or unknown (unknown only for squamous non-small cell lung cancer)\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n6. No previous treatment received\n7. At least 1 measurable lesion as defined by RECIST v1.1\n8. Be able to provide the Informed Consent Form (ICF), and be able to understand and agree to abide by the research requirements and assessment schedule\n9. Good organ function; • Patients have not received blood transfusion or growth factor support therapy ≤ 14 days prior to sample collection during the screening period and: Absolute neutral cell count (ANC) ≥1.5 x 109\u002FL Platelet ≥100 x 109\u002FL Hemoglobin ≥90 g\u002FL • Calculated creatinine clearance (CrCl) (Cockcroft-Gault formula) creatinine clearance ≥ 45 mL\u002Fmin Serum total bilirubin ≤1.5 × upper limit of normal (ULN) (patients with Gilbert\\'s syndrome must have total bilirubin \\< 3 × ULN) AST and ALT≤ 2.5 x ULN Patients who did not receive anticoagulant therapy: International standardized ratio or activated partial thromboplastin time ≤ 1.5 × ULN\n10. Women of childbearing age must take a serum pregnancy test within 3 days before the first medication, and the result is negative. Female subjects of reproductive age and male subjects whose partners are women of reproductive age must agree to use highly effective methods of contraception during the study period and for 120 days after the last dose of the study drug\n\nExclusion Criteria:\n\n1. A history of received treatment for current lung cancer, including radiotherapy and all systemic antitumor agents, including chemotherapy, immunotherapy, targeted therapy or antiangiogenic therapy.\n2. Patients with known EGFR gene mutation, ALK rearrangement, ROS-1 fusion, RET fusion, HER-2 mutation, MET mutation, but if patients with squamous non-small cell lung cancer, the EGFR mutation status and ALK mutation status are unknown, it is not required to conduct tests during screening\n3. There are multiple factors influencing patients taking oral medication (such as inability to swallow, chronic diarrhea, intestinal obstruction)\n4. Allergy to any study drug (Tislelizumab, Anlotinib, albumin-bound Paclitaxel) or excipients.\n5. Imaging shows that the tumor has invaded important blood vessels or the investigator judges that the tumor invasion of important blood vessels during treatment is likely to cause fatal bleeding.\n6. Clinically significant hemoptysis (more than 50 ml per day) within 3 months before the study, or clinically significant bleeding symptoms or obvious bleeding tendency (such as gastrointestinal bleeding, gastric ulcer bleeding, gastrointestinal bleeding, hemorrhagic gastric ulcer, fecal occult blood ++ and above baseline, or suffering from vasculitis, etc.).\n7. Vaccination with attenuated live vaccines within 4 weeks before the first dose or planned vaccination during the study period.\n8. Patients who are expected to be unable to tolerate surgery, such as those with cardiopulmonary insufficiency.\n9. Occurrence of or concurrent other malignancies within the past 5 years, except for cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors \\[Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading the basement membrane)\\].\n10. Patients with active viral hepatitis requiring treatment as determined by the investigator.\n11. Active autoimmune diseases requiring systemic treatment, or long-term use of high doses of steroids or other immunomodulators, which the investigator assesses as affecting the study treatment.\n12. Unhealed surgical incisions before the start of study treatment (small biopsy incisions can be included).\n13. Active hepatitis B\u002FC infection and human immunodeficiency virus (HIV) infection.\n14. Arterial or venous thrombotic events within 6 months (such as cerebrovascular accident, deep vein thrombosis, pulmonary embolism, etc.) or severe cardiovascular diseases: myocardial ischemia or myocardial infarction above grade II, uncontrolled arrhythmias; heart failure above grade III-IV according to NYHA standards, or left ventricular ejection fraction (LVEF) \\\u003C 50% as indicated by echocardiography.\n15. Interstitial lung disease, uncontrolled systemic medical history, including diabetes, hypertension, acute lung disease, etc.\n16. Active bleeding or coagulation dysfunction (INR \\> 2.0, PT \\> 16s), bleeding tendency or receiving thrombolytic, anticoagulant, antiplatelet therapy; any major surgery requiring general anesthesia within ≤ 28 days before the first dose.\n17. Underlying medical conditions or alcohol\u002Fdrug abuse that are unfavorable for the administration of study drugs, may affect the interpretation of results, or pose a high risk of treatment complications.",{"count":165,"type":21},34,[86],"This study is a single-arm prospective clinical trial. The primary objective of the study is to explore the efficacy and safety of preoperative neoadjuvant therapy with Tislelizumab combined with Anlotinib and Nab-Paclitaxel in resectable stage III non-small cell lung cancer.Finally, it provides new evidence-based medical evidence for the perioperative treatment of non-small cell lung cancer.",[169,120,170,171],"NSCLC","Anlotinib","Nab-paclitaxel","2026-06-11",{"date":174,"type":32},"2026-06-15",{"date":176,"type":32},"2025-07-25",{"date":178,"type":21},"2028-07-10",{"name":180,"class":39},"Qilu Hospital of Shandong University",{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":210},"100405378","surveillance-of-complex-renal-cysts---the-socratic-study-100405378","NCT04558593","Surveillance of Complex Renal Cysts - The SOCRATIC Study","SOCRATIC","Inclusion Criteria:\n\n* 18 years old and older;\n* diagnosed with a Bosniak III or IV cyst (classification 2019);\n* size of cystic component ≤7cm;\n* cyst wall\u002Fseptum nodule (obtuse margin of protrusion) \\\u003C10mm (perpendicular axis) or nodular\u002Fsolid component ≤2 cm in any axis;\n* life expectancy \\>5 years (by physician's estimate);\n* new diagnosis ≤ 12 months from accrual date;\n* currently asymptomatic from the disease;\n* deemed fit enough for surgery;\n* willingness and ability to complete questionnaires in either French or English;\n* able and willing to provide informed consent\n\nExclusion Criteria:\n\n* history of a hereditary renal cancer syndrome;\n* presence of polycystic kidney disease;\n* any prior history of RCC;\n* received systemic therapy for another malignancy within the 12 months prior to accrual;\n* uncontrolled medical illness including infections, hypertension, arrhythmias, heart failure, or myocardial infarction\u002Funstable angina within 6 months that would predispose to immediate surgical therapy;\n* metastatic disease or evidence of vascular or nodal disease;\n* unwillingness to undergo monitoring and imaging studies;\n* any contra-indication(s) to contrast-enhanced imaging (estimated glomerular filtration rate \\\u003C30min\u002FmL)",{"count":189,"type":21},330,"One third of individuals aged \\>60 years will be diagnosed with at least one renal cyst following abdominal imaging. These cystic lesions are categorized according to the Bosniak classification which categorizes cysts according to their degree of complexity and risk of malignancy. Growing evidence suggests that a significant proportion of Bosniak III and IV cysts are benign and that the malignant ones present low metastatic potential. Since renal surgery carries substantial morbidity (20%) and potential mortality (0.5%), active surveillance has gained attention as a potential tradeoff to surgery to overcome overtreatment. Therefore, prospective studies of long-term follow-up are needed to confirm the oncologic safety of this strategy for patients with Bosniak III\u002FIV cysts.\n\nThis is an multicenter prospective observational longitudinal study. The main objective is to compare the 5-year follow-up cancer-specific survival between the active surveillance and the surgical groups.",[192],"Complex Renal Cyst",[194,195,196,197,198,199,200,201],"renal cyst","complex cyst","Bosniak III","Bosniak IV","renal masses","active surveillance","monitoring","surgery","2026-05-27",{"date":151,"type":32},{"date":205,"type":32},"2021-02-02",{"date":207,"type":21},"2031-09-20",{"name":209,"class":39},"Université de Sherbrooke",18,{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":82,"enrollmentInfo":218,"targetDuration":4,"studyType":51,"phases":220,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":130},"100605437","phase-2-dcrt-vs-surgery-in-resectable-escc-patient-achiving-ccrpr-after-nci-100605437","NCT07162506","DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR\u002FPR After nCI","Definitive Concurrent Chemoradiotherapy Versus Surgery in Patients With Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (ESCC) Who Achieve Complete or Partial Response After Neoadjuvant Chemo-immunotherapy: A Two-arm Phase II Clinical Study (SORT Trial)","Inclusion Criteria:\n\n1. Volunteered to participate, cooperated with follow-up visits.\n2. Aged 18 - 75 years (inclusive), male or female.\n3. Histologically confirmed locally advanced resectable ESCC, clinically staged as Stage II - IVa (cT1N1-3M0, cT2-4aN0-3M0 before treatment; 8th AJCC), and achieve cCR\u002FPR after 2-3 cycles of platinum-based chemotherapy combined with anti-PD-1 or PD-L1 monoclonal antibodies.\n4. Presence of measurable and\u002For non-measurable lesions as defined by Japanese Classification of Esophageal Cancer (12th Edition);\n5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.\n6. Estimated survival time ≥ 3 months.\n7. The function of major organs meets the following requirements:\n\n   1. Absolute neutrophil count (ANC) ≥ 1.5×10\\^9\u002FL;\n   2. Platelets ≥ 80×10\\^9\u002FL;\n   3. Hemoglobin ≥ 9g\u002FdL;\n   4. Serum albumin ≥ 2.8g\u002FdL;\n   5. Total bilirubin ≤ 1.5 × ULN, ALT, AST and\u002For ALP ≤ 2.5 × ULN;\n   6. Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60mL\u002Fmin;\n   7. International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5× ULN (subjects on stable doses of anticoagulation therapy, such as low molecular weight heparin or warfarin, and with INR within the expected therapeutic range of the anticoagulant can be screened);\n8. Comprehensive baseline staging evaluation prior to induction chemo-immunotherapy, including esophagogastroduodenoscopy (with biopsy) and\u002For endoscopic ultrasonography (EUS), contrast-enhanced CT of the neck, chest, and upper abdomen (with or without PET-CT), magnetic resonance imaging (MRI) without MRI contraindications, and upper gastrointestinal contrast.\n9. Patients of childbearing potential must use a medically approved contraceptive method (such as intrauterine device, contraceptive pills, or condoms) during the study treatment period and within 6 months after the end of the study treatment; serum Human Chorionic Gonadotropin (HCG) or urine HCG test must be negative within 72 hours before study enrollment; and must not be breastfeeding.\n\nExclusion Criteria:\n\n1. Surgery for esophageal cancer;\n2. Esophageal fistulae due to infiltration of the primary tumor；\n3. Risk of gastrointestinal bleeding, esophageal fistula or esophageal perforation;\n4. Poor nutritional status, weight loss of ≥10% in the previous 2 months, with no significant improvement after nutritional intervention;\n5. Major surgery or severe trauma within 4 weeks prior to first use of study drug;\n6. Uncontrollable pleural effusion, pericardial effusion, or ascites that requires repeated drainage;\n7. Received or receiving any of the following treatments in the past:\n\n   1. Radiotherapy or targeted therapy;\n   2. Participation in a study of an investigational agent or device within 4 weeks before the first dose of study treatment;\n   3. Systemic treatment with corticosteroids (\\>10 mg prednisone equivalent dose per day) or other immunosuppressive agents is required for 2 weeks before the first dose of study treatment (except for the use of corticosteroids for local inflammation of the esophagus and for the prevention of allergy and nausea and vomiting). Other special circumstances need to be communicated to the sponsor. Inhaled or topical steroids and adrenocorticotropic hormone replacement at doses \\>10mg\u002Fday prednisone efficacy dose are permitted if the patient does not have active autoimmune disease;\n   4. Received an anti-tumour vaccine or received a live vaccine within 4 weeks before the first dose of study treatment;\n8. Any active autoimmune disease or history of autoimmune disease (e.g., interstitial pneumonitis, uveitis, enteritis, hepatitis, pituitary gland inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism); Except for patients with vitiligo or those who had asthma or allergies in childhood but did not need any intervention as adults; patients with autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormone and type I diabetes mellitus treated with stable doses of insulin may be included;\n9. Diagnosis of immunodeficiency, including positive HIV test, other acquired\u002Fcongenital immunodeficiency diseases, organ transplantation and allogeneic bone marrow transplantation;\n10. Diagnosis of uncontrolled cardiac clinical symptoms or disease such as: a. NYHA II or above heart failure; b. unstable angina; c. myocardial infarction within 1 year; d. clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention;\n11. Severe infections (CTCAE \\> grade 2), such as severe pneumonia requiring hospitalisation, bacteraemia, infectious co-morbidities, etc., within 4 weeks before the first use of study treatment; Baseline chest imaging suggestive of active lung inflammation, signs and symptoms of infection requiring oral or intravenous antibiotic treatment within 2 weeks before the first use of study treatment, except for prophylactic antibiotic use;\n12. History of interstitial lung disease or non-infectious pneumonia, or pulmonary insufficiency ≥ grade 3 as confirmed by pulmonary function tests;\n13. Active tuberculosis infection detected by history or CT examination, or history of active tuberculosis infection within 1 year before enrollment or more than 1 year previously without regular treatment;\n14. Presence of active hepatitis B (HBV DNA ≥ 2000 IU\u002FmL or 104 copies\u002FmL), hepatitis C (hepatitis C antibody positive and HCV-RNA above the lower limit of detection);\n15. Presence of abnormal sodium, potassium, and calcium laboratory test values greater than grade 1 within 2 weeks prior to enrollment that do not improve with treatment;\n16. Known hypersensitivity to large protein preparations, or to any of the components of camrelizumab, or anaphylaxis, hypersensitivity, or contraindication to paclitaxel or carboplatin or to any of the components used within their preparations;\n17. Previously diagnosed with any other malignancy within 5 years before the first use of the investigational drug, except for malignancies with low risk of metastasis and death (5-year survival rate\\>90%), such as adequately treated basal cell or squamous cell skin cancer or cervical carcinoma in situ.\n18. As judged by the investigator, the subject has other factors that may lead to forced termination of the study midway.",{"count":219,"type":21},120,[86],"This is a multi-center, Phase II clinical study aiming to evaluate the efficacy, safety, and organ preservation feasibility of definitive concurrent chemoradiotherapy versus surgery in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC) who achieve clinical complete response\u002Fpartial response (cCR\u002FPR) after neoadjuvant chemo-immunotherapy.\n\nA total of 120 eligible subjects will be enrolled. Patients with cCR\u002FPR after 2-3 cycles of neoadjuvant chemo-immunotherapy will be grouped based on personal willing: the control group (n=60) will receive radical esophagectomy + mediastinal lymph node dissection; the experimental group (n=60) will receive definitive concurrent chemoradiotherapy (radiotherapy: 50.4 Gy\u002F28f; chemotherapy: nab-paclitaxel 175mg\u002Fm² + carboplatin AUC=5, q21d for 2 cycles). All the patients will receive camrelizumab maintenance therapy (200mg q21d) up to 1 year.",[25],"2026-05-26",{"date":225,"type":32},"2026-05-29",{"date":227,"type":32},"2025-11-03",{"date":229,"type":21},"2030-08-30",{"name":231,"class":39},"Tianjin Medical University Cancer Institute and Hospital",{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":17,"minAge":240,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":51,"phases":243,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":256,"leadSponsor":258,"locationsCount":130},"100641009","phase-2-preoperative-radiotherapy-and-anlotinib-with-or-without-penpulimab-for-soft-tissue-sarcoma-100641009","NCT07612098","Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue Sarcoma","A Prospective Multicenter Randomized Controlled Study of Preoperative Radiotherapy Combined With Targeted Therapy With or Without Immunotherapy for Soft Tissue Sarcoma","SPARE-04","Inclusion Criteria:\n\n* Primary or recurrent soft tissue sarcoma of the extremity or trunk with intermediate- to high-grade disease and tumor size \\>=5 cm or deep-seated tumor, for which radiotherapy is recommended after multidisciplinary evaluation.\n* Age \\>=15 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3.\n* Histologically confirmed soft tissue sarcoma.\n* At least one evaluable lesion.\n* Able to tolerate radiotherapy, anlotinib, and penpulimab treatment.\n* Female participants of childbearing potential, or male participants with female partners of childbearing potential, must agree to use effective contraception during the treatment period and for 6 months after the last dose of study treatment.\n* Able to provide written informed consent.\n* Able and willing to comply with follow-up.\n\nExclusion Criteria:\n\n* No gross tumor remaining after unplanned tumor resection performed at another hospital.\n* Contraindications to targeted therapy or immunotherapy due to comorbidities, including allergy, autoimmune disease, active bleeding, ulcer, intestinal perforation, intestinal obstruction, uncontrolled hypertension, New York Heart Association class III-IV cardiac dysfunction, or severe hepatic or renal dysfunction.\n* Dermatofibrosarcoma protuberans, desmoid fibromatosis, tenosynovial giant cell tumor, or other locally aggressive diseases.\n* Benign tumors.\n* Sarcoma subtypes for which chemotherapy is recommended as the preferred neoadjuvant treatment according to guidelines, such as embryonal rhabdomyosarcoma or Ewing sarcoma.\n* Lipoma-like liposarcoma or well-differentiated liposarcoma.\n* New malignant tumor within 5 years before enrollment, except cervical carcinoma in situ, early-stage basal cell carcinoma of the skin, or early-stage lung cancer.\n* Soft tissue sarcoma that can be cured by wide local excision alone.\n* Prior radiotherapy to the same anatomical site.\n* Other severe medical comorbidities that would preclude surgery or participation in this study.","15 Years",{"count":242,"type":21},274,[86],"Soft tissue sarcoma is a rare cancer that often requires surgery combined with radiotherapy. Preoperative radiotherapy can improve the chance of complete tumor removal and limb preservation, but some patients still experience local recurrence, distant metastasis, or poor tumor response.\n\nThis is a prospective, multicenter, randomized phase II study for patients with localized soft tissue sarcoma of the extremity or trunk who need preoperative radiotherapy. Participants will be randomly assigned to receive preoperative radiotherapy plus anlotinib, or preoperative radiotherapy plus anlotinib and penpulimab. Surgery will be performed after completion of neoadjuvant treatment according to the study protocol.\n\nThe main purpose of this study is to evaluate whether adding penpulimab to preoperative radiotherapy and anlotinib can improve 3-year disease-free survival. The study will also assess pathological response, wound complications, treatment-related adverse events, local control, distant metastasis-free survival, overall survival, limb function, quality of life, and exploratory biomarkers related to treatment response.",[246],"Soft Tissue Sarcoma (STS)",[248,249,250,170,251],"Soft Tissue Sarcoma","Preoperative Radiotherapy","Neoadjuvant Therapy","Penpulimab","2026-05-21",{"date":254,"type":32},"2026-05-28",{"date":66,"type":21},{"date":257,"type":21},"2031-12-31",{"name":259,"class":39},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":51,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":286},"100364933","phase-3-surgery-with-or-without-neoadjuvant-chemotherapy-in-high-risk-retroperitoneal-sarcoma-100364933","NCT04031677","Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma","A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS)","STRASS2","1. STRASS 2\n\n   Inclusion Criteria:\n   * Histologically proven primary high risk leiomyosarcoma (LMS) or Liposarcoma (LPS) of retroperitoneal space or infra-peritoneal spaces of pelvis.\n   * LMS:\n\n     * Any grade LMS can be included\n     * Minimum size of LMS tumor should be 5 cm\n   * LPS:\n\n     * Diagnosis should be confirmed based on MDM2 (Mouse double minute 2 homolog) and CDK4 (Cyclin-dependent kinase 4) expression on IHC (immunohistochemistry), while proof of MDM2 amplification is highly recommended.\n     * All grade 3 DDLPS can be included.\n     * DDLPS with confirmed grade 2 on biopsy can be included when:\n\n       * The grade 2 DDLPS has an FNCLCC score=5 (Fédération Nationale des Centres de Lutte Contre Le Cancer), and clear necrosis on imaging (whether or not present on the biopsy).\n       * The tumors carry a high risk gene profile as determined by the Complexity INdex in SARComas (CINSARC-high)\n     * Unifocal tumour\n     * Resectable tumour: resectability is based on pre-operative imaging (CT-abdomen, potentially also with MRI) and has to be defined by the local treating sarcoma team. A patient is not considered resectable when the expectation is that only an R2 resection is feasible.\n     * Criteria for non-resectability are:\n     * Involvement of the superior mesenteric artery, aorta, coeliac trunk and\u002For portal vein\n     * Involvement of bone\n     * Growth into the spinal canal\n     * Progression of retro-hepatic inferior vena cava leiomyosarcoma towards the right atrium\n     * Infiltration of multiple major organs like liver, pancreas and or major vessels\n     * Patient must have radiologically measurable disease (RECIST 1.1), as confirmed by imaging. CT thorax abdomen pelvis with IV contrast is the preferred imaging modality. In case of any contra-indications (medical or regulatory), it is allowed to perform a non-contrast CT thorax + MRI abdomen \\& pelvis\n     * Collection of tumour tissue for central pathology review is mandatory.\n     * For patients with LMS: if there is not enough tissue for assessing the grading, this is acceptable.\n     * If tumour tissue is not available for the central pathology review, patient will not be eligible.\n     * If the biopsy was not done or the FFPE of the biopsy not available but at least 10 unstained slides or one pathological block are available for the central review, that will be considered as acceptable.\n     * For the biopsy if fine needle aspiration (FNA) is performed instead of core needle biopsy (CNB) recommended by the standard guidelines, please contact the EORTC medical monitors for further evaluation.\n     * Collection of tumour tissue and blood samples for translational research is mandatory.\n     * In case there is not enough tissue for TR, a new biopsy is not required and if the patient fulfils all other eligibility criteria, he\u002Fshe will be eligible.\n     * If the blood samples are not collected, patient will not be eligible.\n     * If the patient refuses the collection of biomaterial for TR, patient will not be eligible even if he\u002Fshe fulfils all other eligibility criteria\n     * ≥ 18 years old (no upper age limit)\n     * WHO performance status ≤ 2\n     * Adequate haematological and organ function\n     * American Society of Anaesthesiologist (ASA) score \\\u003C 3\n     * Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 3 days prior to randomization.\n\n   Note: a woman is considered of childbearing potential, i.e., fertile, if she is following menarche. She remains of childbearing potential until she becomes post-menopausal or permanently sterile.Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.\n\n   A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 consecutive months without menses, a single FSH measurement is insufficient.\n   * WOCBP in both arms should use highly effective birth control measures, during the study treatment period and for at least 6 months after the last dose of chemotherapy or date of surgery (except for women receiving chemotherapy with ifosfamide who should continue contraception until 1 year after last day of treatment). A highly effective method of birth control is defined as a method which results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly.\n   * For men in the experimental arm: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm.\n   * Female subjects who are breast feeding should discontinue nursing prior to the first day of study treatment and until 6months after the last study treatment.\n   * Before patient randomization, written informed consent must be given according to ICH\u002FGCP, and national\u002Flocal regulations.\n\n   Exclusion criteria:\n   * Sarcoma originating from bone structure, abdominal or gynecological viscera\n   * Extension through the sciatic notch or across the diaphragm\n   * Metastatic disease\n   * Any previous surgery (excluding diagnostic biopsy), radiotherapy or systemic therapy for the present tumour\n   * Hypersensitivity to doxorubicin, ifosfamide, dacarbazine or to any of their metabolites or to any of their excipients\n   * Congestive heart failure\n   * Angina pectoris\n   * Myocardial infarction within 1 year before randomization\n   * Uncontrolled arterial hypertension defined as blood pressure ≥ 150\u002F100 mm Hg despite optimal medical therapy.\n\n   Note: in case of high blood pressure: 1) initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; 2) blood pressure must be re-assessed on two occasions that are separated by a minimum of 1 hour. The mean SBP \u002F DBP values from each blood pressure assessment must be ≤ 150\u002F90mmHg in order for a patient to be eligible for the study.\n   * Uncontrolled cardiac arrhythmia\n   * Previous treatment with maximum cumulative doses (450mg\u002Fm² Doxorubicin or equivalent 900mg\u002Fm² Epirubicin) of doxorubicin, daunorubicin, epirubicin, idarubicin, and\u002For other anthracyclines and anthracenediones\n   * Active and uncontrolled infections\n   * Vaccination with live vaccines within 30 days prior to study entry\n   * Inflammation of the urinary bladder (interstitial cystitis) and\u002For obstructions of the urine flow.\n   * Other invasive malignancy within 5 years, with the exception of adequately treated non-melanoma skin cancer, localized cervical cancer, localized and Gleason ≤ 6prostate cancer.\n   * Uncontrolled severe illness, infection, medical condition (including uncontrolled diabetes), other than the primary LPS or LMS of the retroperitoneum.\n   * Female patients who are pregnant or breastfeeding or female and male patients of reproductive potential who are not willing to employ effective birth control method.\n   * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before randomization in the trial\n   * Known contraindication to imaging tracer and to MRI\n2. Selection criteria for STREXIT 2\n\n   * Patients with histologically proven primary resectable localized high-risk DDLPS or LMS of retroperitoneal space or infra-peritoneal spaces of pelvis (as described in the inclusion criteria of STRASS 2) and amenable to receive chemotherapy but for whom the list of eligibility criteria for the study is too restrictive (tumour grading not available, inadequate organ function, concomitant diseases)\n   * Patients who meet all eligibility criteria of STRASS 2 but do not consent to randomization or are not enrolled for any other reason.\n   * Patients enrolled in a Registry collecting data on primary RPS patients in the centres participating in STRASS 2 (e.g., RESAR) and who satisfy the above criteria.\n3. Selection criteria for preferences for neoadjuvant chemotherapy in STRASS 2 substudy\n\nAll patients recruited to STRASS 2 in participating centres (Australia +\u002F- international sites) that are able to read, comprehend and write in English at a sufficient level to complete study materials.",{"count":269,"type":21},250,[53],"This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival.\n\nAfter confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.",[273,274,275],"Retroperitoneal Sarcoma","Liposarcoma","Leiomyosarcoma","2026-05-20",{"date":278,"type":32},"2026-05-22",{"date":280,"type":32},"2021-01-20",{"date":282,"type":21},"2028-04-21",{"name":284,"class":285},"European Organisation for Research and Treatment of Cancer - EORTC","NETWORK",169,{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":294,"enrollmentInfo":295,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":297,"conditions":298,"keywords":300,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":130},"100211065","metabolic-responses-to-bariatric-surgery-100211065","NCT02024542","Metabolic Responses to Bariatric Surgery","Genetic and Biochemical Characteristics of Medically-Complicated Obesity and Response to Bariatric Surgery","Inclusion Criteria:\n\n* Meet NIH Criteria for Bariatric Surgery\n* Between the Age of 18-55\n* Dyslipidemia controlled with medication\n* Impaired glucose metabolism or type 2 diabetes\n\nExclusion Criteria:\n\n* Uncontrolled Metabolic syndrome (uncontrolled diabetes, htn, dyslipidemia), one or all conditions.","55 Years",{"count":296,"type":21},500,"Research the genetic and biomechanical markers of human adipose tissue on patients with morbid obesity. Additional tissue\u002Ffluid collection is also gathered during the time of surgery.",[299],"Morbid Obesity",[301,302,303,304,305],"Bariatric Surgery","Obesity","Metabolic syndrome","Diabetes","Liver Disease","2026-05-14",{"date":308,"type":32},"2026-05-18",{"date":310,"type":4},"2011-02",{"date":312,"type":21},"2035-04",{"name":314,"class":39},"University of California, Davis",{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":51,"phases":325,"briefSummary":326,"conditions":327,"keywords":329,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":343},"100570037","phase-2-the-minimalist-trial-2-100570037","NCT06702033","The Minimalist Trial-2","Phase II Trial of Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: \"The Minimalist Trial-2 (MINT-2)\"","MINT-2","Inclusion Criteria:\n\n* Histologically or cytologically confirmed HPV-related, clinical stages I-II OPSCC (8th edition of AJCC\u002FUICC Staging Manual) or HPV-related neck node with unknown primary. Clinical T1N0M0 and T2N0M0 disease are excluded. HPV-related may be defined by p16 IHC stain and\u002For HPV-High Risk RNA ISH\u002FHPV DNA genotyping by PCR, using standard definitions of positive and negative test results.\n* Planned resection of the primary tumor site by a transoral approach (TORS, TLM, or conventional surgery).\n* Planned unilateral or contralateral selective neck dissection.\n* ECOG PS 0-2.\n* Adequate organ and marrow function defined as:\n\n  * Creatinine clearance ≥ 50 mL\u002Fmin.\n  * ANC ≥ 1.0 K\u002Fcumm.\n  * Platelet count ≥100 K\u002Fcumm.\n* At least 18 years of age.\n* Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria:\n\n* Clinical T1N0M0 or T2N0M0 disease.\n* Prior radiation therapy for HNSCC.\n* Planned free-flap reconstruction of the resected primary site.\n* Cirrhosis with Child-Pugh Score B or C.\n* History of prior invasive malignancy diagnosed within 2 years prior to study enrollment; exceptions are malignancies with a low risk of metastasis or death (e.g., expected 5-year OS \\> 90%) that were treated with curative-intent therapy.\n* Receiving any other investigational agents.\n* Uncontrolled serious inter-current illness or serious psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant and\u002For breastfeeding. A negative serum pregnancy test is required at screening for all female patients of childbearing potential.",{"count":324,"type":21},142,[86],"Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer. Oropharynx SCC (OPSCC) is a common sub-type of HNSCC. Each year, 16,000 new cases of OPSCC are diagnosed in the USA. Most cases of OPSCC (\\>90%) are caused by the human papillomavirus (HPV) and are often cured with current therapy.\n\nHowever, patients treated with surgery followed by postoperative adjuvant chemotherapy and radiation therapy (POA(C)RT) still experience substantial morbidity. In this highly curable disease, current clinical research interest is focused on investigation of de-escalated therapy, with the goal to reduce treatment-related adverse events (AEs) while maintaining a low recurrence rate.\n\nIn this study, patients with HPV-related OPSCC will undergo resection of the primary tumor site and involved\u002Fat-risk regional neck nodes. Based on the pathology report, patients will be assigned to:\n\n* Arm 1 (de-POACRT-42 Gy)\n* Arm 2A (de-POART-42 Gy)\n* Arm 2B (de-POART-37.8 Gy)\n* Arm 2C (de-POACRT-30 Gy).\n\nAll patients with high-risk pathology will be assigned to Arm 1 whereas patients with intermediate-risk pathology will be randomized (1:1:1) to Arm 2A, Arm 2B, or Arm 2C. Patients with highest-risk pathology and low-risk pathology will be removed from the trial after surgery and will be advised to pursue standard of care options.",[328],"HPV-Related Oropharynx Squamous Cell Carcinoma",[330,331,332,333],"De-escalation","Adjuvant therapy","Oropharyngeal cancer","Human papillomavirus","2026-05-12",{"date":336,"type":32},"2026-05-15",{"date":338,"type":32},"2025-04-10",{"date":340,"type":21},"2033-07-15",{"name":342,"class":39},"Washington University School of Medicine",3,{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":351,"enrollmentInfo":352,"targetDuration":4,"studyType":51,"phases":354,"briefSummary":355,"conditions":356,"keywords":359,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":156},"100556713","phase-2-entrectinib-as-a-single-agent-in-upfront-therapy-for-children-3-years-of-age-with-ntrk123-or-ros1-fused-cns-tumors-100556713","NCT06528691","Entrectinib as a Single Agent in Upfront Therapy for Children \u003C3 Years of Age With NTRK1\u002F2\u002F3 or ROS1-FUSED CNS Tumors","PHASE 2 Study of Entrectinib as a Single Agent in Upfront Therapy for Children \u003C3 Years of Age With NTRK1\u002F2\u002F3 or ROS1-FUSED CNS Tumors (GLOBOTRK)","Inclusion Criteria: Screening Phase\n\n* Age from birth to age \\\u003C3 years at the time of diagnosis (date of surgical resection\u002Fbiopsy)\n* Participant with presumed newly diagnosed tumor in the supratentorial compartment\n* Patient must have measurable disease based on RAPNO criteria\n* ≤84 days since surgery (resection or biopsy)\n* Available tumor tissue for central review\n* Parent\u002Fguardian has the ability to understand and the willingness to sign a written informed consent document according to institutional guidelines\n\nExclusion Criteria: Screening Phase\n\n* Previous exposure to cytotoxic chemotherapy or radiotherapy\n\nInclusion Criteria: COHORT 1\n\n* Patients must be \\\u003C3 years of age at the time of diagnosis (date of surgical resection\u002Fbiopsy)\n* High-grade glioma (World Health Organization \\[WHO\\] grade III or IV) harboring NTRK1\u002F2\u002F3 or ROS1 gene fusions as determined by central pathology review\n* Patients must have measurable disease as defined by RAPNO criteria\n* Patients are eligible at the time of diagnosis, prior to any exposure to chemotherapy, targeted therapy, immunotherapy, cellular therapy or radiation\n* ≤28 days since study screening\n* Lansky score ≥50% and a minimum life expectancy of ≥ 12 weeks\n* Neurologic deficits must have been stable for at least 7 days prior to study enrollment\n* Hemoglobin ≥ 8 g\u002FdL (without transfusion or erythropoietin use within 7 days prior to enrollment)\n* Platelet count ≥ 75,000\u002FµL (without transfusion within 7-day period prior to enrollment)\n* Absolute neutrophil count \\>1,000\u002FµL\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5x the upper limit of normal (ULN)\n* Bilirubin ≤ 1.5 x ULN\n* Adequate renal function as defined by the following age-based serum creatinine concentrations:\n\n  * 0 to \\\u003C1 year: 0.5 mg\u002FdL\n  * 1 to \\\u003C2 years: 0.6 mg\u002FdL\n  * 2 to 3 years: 0.8 mg\u002FdL\n* Adequate cardiac function as defined by electrocardiogram (ECG) with Fridericia's corrected QT interval (QTc) ≤ 450 msec and echocardiogram left ventricular ejection fraction (LVEF) \\>50%\n* Screening and enrollment consents signed\n* Willingness and ability to comply with treatment plan, scheduled visits, laboratory tests and other study procedures\n\nInclusion Criteria: COHORT 2\n\n* Patients must be \\\u003C3 years of age at the time of diagnosis (date of surgical resection\u002Fbiopsy)\n* CNS tumor other than HGG harboring NTRK1\u002F2\u002F3 or ROS1 gene fusions as determined by central pathology review\n* Patients must have measurable disease as defined by RAPNO criteria\n* Patients are eligible at the time of diagnosis, prior to any exposure to chemotherapy, targeted therapy, immunotherapy, cellular therapy or radiation\n* ≤28 days since study screening\n* Lansky score ≥50% and a minimum life expectancy of ≥ 12 weeks\n* Neurologic deficits must have been stable for at least 7 days prior to study enrollment.\n* Hemoglobin ≥ 8 g\u002FdL (without transfusion or erythropoietin use within 7 days prior to enrollment)\n* Platelet count ≥ 75,000\u002FµL (without transfusion within 7-day period prior to enrollment);\n* Absolute neutrophil count \\>1,000\u002FµL.\n* ALT and ALT ≤2.5x the upper limit of normal (ULN)\n* Bilirubin ≤ 1.5 x ULN\n* Adequate renal function as defined by the following age-based serum creatinine concentrations:\n\n  * 0 to \\\u003C1 year: 0.5 mg\u002FdL\n  * 1 to \\\u003C2 years: 0.6 mg\u002FdL\n  * 2 to 3 years: 0.8 mg\u002FdL\n* Adequate cardiac function as defined by ECG with QTc ≤ 450 msec and echocardiogram LVEF \\>50%\n* Screening and enrollment consents signed\n* Willingness and ability to comply with treatment plan, scheduled visits, laboratory tests and other study procedures\n\nExclusion Criteria: COHORT 1 AND 2\n\n* Clinically significant medical disorder that could compromise the ability to tolerate study therapy or would interfere with the study procedures or results history\n* History of recent (3 months) symptomatic congestive heart failure\n* Known active, uncontrolled infection (bacterial, fungal, or viral)\n* Receiving enzyme inducing antiepileptic drugs (EIAEDs)\n* Any prior cancer therapy including chemotherapy (excluding Bridging Chemotherapy Cycle), targeted therapy, immunotherapy, cellular therapy, or radiation\n* Receiving another investigational agent concurrently\n* Surgery within 2 weeks prior to treatment enrollment\n* Patients with known hypersensitivity to excipients of the investigational medicinal product\n* Active gastrointestinal disease or malabsorption disorder (e.g. Crohn's disease, ulcerative colitis, short-gut syndrome) that would impair drug absorption\n* Inability to take medication enterally","3 Years",{"count":353,"type":21},52,[86],"This clinical trial tests how well entrectinib works to treat patients less than 3 years of age with NTRK 1\u002F2\u002F3 or ROS1 fused, high grade glioma or other central nervous system (CNS) tumors.",[357,358],"High Grade Glioma","CNS Tumor",[360,361,362,363,364,365],"CNS Tumors","High Grade Glioma with NTRK1\u002F2\u002F3 gene fusion","High Grade Glioma with ROS1 gene fusion","CNS tumor other than HGG harboring NTRK1\u002F2\u002F3 gene fusion","CNS tumor other than HGG harboring ROS1 gene fusion","Children",{"date":367,"type":32},"2026-05-13",{"date":369,"type":32},"2026-05-01",{"date":371,"type":21},"2032-11",{"name":373,"class":39},"St. Jude Children's Research Hospital",{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":82,"enrollmentInfo":382,"targetDuration":4,"studyType":51,"phases":384,"briefSummary":386,"conditions":387,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":389,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":40},"100315670","early-mitral-valve-repair-versus-watchful-waiting-for-asymptomatic-severe-degenerative-mitral-regurgitation-100315670","NCT03389542","Early Mitral ValvE Repair Versus Watchful Waiting for Asymptomatic SEvere Degenerative Mitral Regurgitation","Randomized Comparison of Early Mitral ValvE Repair Versus Watchful Waiting for Asymptomatic SEvere Degenerative Mitral Regurgitation Due to Leaflet Prolapse","REVERSE-MR","Inclusion Criteria:\n\n* Asymptomatic patients according history or an exercise test in those able to perform it if there is a doubt about the absence of symptoms\n* Severe (grade IV) degenerative MR due to leaflet prolapse assessed by echocardiography\n* LV ejection fraction by Simpson biplane method ≥60% and LV end-systolic diameter by TM echocardiography ≤40mm\n* Sinus rhythm on the inclusion ECG\n* Pulmonary artery pressure ≤50 mmHg by Doppler echocardiography.\n* High probability of mitral valve repair\n* EuroSCORE II ≤ 3%\n\nExclusion Criteria:\n\n* Mitral stenosis or \\> mild aortic valve disease (stenosis or regurgitation)\n* Congenital heart disease (except patent foramen ovale or atrial septal defect)\n* Patients with cardiac prostheses\n* Previous myocardial infarction\n* Previous cardiac surgery\n* Extra cardiac comorbidity with life expectancy \\\u003C 5 years\n* Recent history of psychiatric disease (including drug or alcohol abuse)\n* Therapy with an investigational intervention at the time of screening or plan to enrol patient in additional intervention study during participation in this trial",{"count":383,"type":21},424,[385],"NA","Degenerative mitral regurgitation (MR) due to leaflet prolapse is frequent and can be surgically repaired in the vast majority of patients. Despite the efficacy of mitral valve repair, an ongoing international controversy exists regarding the need to perform early surgery in asymptomatic patients with severe MR and no sign of LV dysfunction in whom the probability of successful and durable repair is very high. In this group of patients, differing views of the risks of uncorrected severe MR exist: considered as benign by those supporting medical \"watchful waiting\" or associated with significant excess mortality\u002Fmorbidity by those advocating early surgery. This controversy can only be resolved by a randomized controlled trial which is still lacking.\n\nThe main objective is to demonstrate the superiority of early mitral valve repair in patients with asymptomatic severe MR due to leaflet prolapse compared to an initial conservative management in terms of all-cause death and cardiovascular morbidity during five years follow-up.",[388],"Degenerative Mitral Regurgitation (MR) Due to Leaflet Prolapse",{"date":367,"type":32},{"date":391,"type":32},"2018-04-10",{"date":393,"type":21},"2033-04-10",{"name":395,"class":39},"Centre Hospitalier Universitaire, Amiens",{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":12,"sex":81,"minAge":48,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":51,"phases":406,"briefSummary":407,"conditions":408,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":418},"100543638","stratification-of-vulvar-scc-by-hpv-and-p53-status-to-guide-excision-100543638","NCT06358469","STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision","STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision","STRIVE","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of vulvar squamous cell carcinoma (VSCC)\n* Surgically staged FIGO I-II VSCC as per FIGO 2021 guidelines\n* Vulvar resection according to standard of care guidelines\n* Post-operative margin assessment of tumour clearance, dVIN and p53 status.\n* Participants' age must be ≥ 18 years old\n* Participant is able (i.e. sufficiently fluent) and willing to complete the quality of life and\u002For health utility questionnaires in either English or French\n* Participant's consent must be appropriately obtained in accordance with applicable local and regulatory requirements\n\nExclusion Criteria:\n\n* Recurrent vulvar squamous cell carcinoma\n* Non-squamous cell carcinoma histotypes\n* Participants referred for\u002Freceiving\u002For previously received adjuvant vulvar radiation or chemotherapy\n* Primary tumour HPV-I p53 wild-type VSCC\n* Surgical margins positive for invasive cancer.\n* Participants with a history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for ≥ 5 years\n* Lymph node positive VSCC or lymph nodes with isolated tumour cells.",{"count":405,"type":21},249,[385],"This study is being done to answer the following question: Are there types of early-stage vulvar cancer that require either less or more treatment than the usual approach?",[409],"Vulvar Squamous Cell Carcinoma","2026-05-11",{"date":334,"type":32},{"date":413,"type":32},"2024-12-10",{"date":415,"type":21},"2031-11-30",{"name":417,"class":285},"Canadian Cancer Trials Group",11,{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":82,"enrollmentInfo":427,"targetDuration":4,"studyType":51,"phases":429,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":435,"completionDateStruct":436,"leadSponsor":438,"locationsCount":4},"100638289","phase-2-adebrelimab-plus-full-course-neoadjuvant-therapy-for-resectable-locally-advanced-escc-phase-2-100638289","NCT07584031","Adebrelimab Plus Full-course Neoadjuvant Therapy for Resectable Locally Advanced ESCC (Phase 2)","A Prospective, Single-Center, Phase II Clinical Trial of Adebrelimab Combined With Full-Course Neoadjuvant Therapy for Watchful Waiting or Surgery in Patients With Resectable Locally Advanced Esophageal Squamous Cell Carcinoma","NAT-ESCC-01","Inclusion Criteria:\n\n* Patients voluntarily participate in this study, sign an informed consent form, and demonstrate good compliance;\n* At least 18 years of age; gender is not restricted;\n* ECOG performance status: 0-1;\n* Patients with histologically confirmed resectable esophageal squamous cell carcinoma clinically staged as (T1N+M0 or T2-4aNanyM0);\n* No prior anticancer therapy for esophageal cancer, including chemotherapy, hormone therapy, radiation therapy, or immunotherapy;\n* Laboratory tests must meet the following criteria (within 7 days prior to baseline enrollment):\n\n  1. Complete blood count (CBC):\n\n     1. Hemoglobin (Hb) ≥ 90 g\u002FL (no blood transfusion within the past 14 days);\n     2. Neutrophil count (NEUT) ≥ 1.5 × 10⁹\u002FL;\n     3. Platelet count (PLT) ≥ 100 × 10⁹\u002FL;\n     4. White blood cell count (WBC) ≥ 3 × 10⁹\u002FL;\n  2. Biochemical Tests:\n\n     1. Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5×ULN;\n     2. Serum total bilirubin (TBIL) ≤ 1.5×ULN;\n     3. Serum creatinine (Cr) ≤ 1.5×ULN; (or creatinine clearance (CCr) ≥ 60 mL\u002Fmin);\n  3. Coagulation function: Activated partial thromboplastin time (APTT), International Normalized Ratio (INR), and prothrombin time (PT) ≤ 1.5×ULN;\n  4. Thyroid function: Thyroid-stimulating hormone (TSH) ≤ ULN (if abnormal, FT3 and FT4 levels should also be evaluated; if FT3 and FT4 levels are normal, the patient may be enrolled);\n  5. Doppler ultrasound assessment: Left ventricular ejection fraction (LVEF) ≥50%;\n* Female participants must agree to use contraceptive measures, such as an intrauterine device (IUD), oral contraceptives, or condoms, during the study and for 6 months after study completion; they must have a negative serum pregnancy test within 7 days prior to study enrollment and must not be breastfeeding; male participants must agree to use contraceptive measures during the study and for 6 months after study completion.\n\nExclusion Criteria:\n\n* Concurrent malignant neoplasms (except for cured basal cell carcinoma of the skin);\n* Diagnosis of cervical esophageal cancer;\n* History of severe hypersensitivity reactions following administration of other monoclonal antibodies;\n* Presence of any active autoimmune disease or history of autoimmune disease (such as, but not limited to: autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, or nephritis; asthma requiring bronchodilators for medical intervention); however, the following patients are eligible for enrollment: vitiligo, psoriasis, or alopecia not requiring systemic treatment; well-controlled type 1 diabetes; hypothyroidism with normal thyroid function following replacement therapy;\n* Requiring immunosuppressants, or systemic or absorbable topical corticosteroids for immunosuppressive purposes (dose \\> 10 mg\u002Fday of prednisone or other corticosteroids of equivalent potency), and still using them within 2 weeks of the first dose;\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage;\n* Uncontrolled symptoms of brain metastases, spinal cord compression, or carcinomatous meningitis occurring within 4 weeks prior to the first dose, or patients with brain or meningeal disease identified by CT or MRI at screening;\n* Patients with any severe and\u002For uncontrolled medical conditions, including:\n\n  1. Acute or recurrent myocardial ischemia or myocardial infarction; poorly controlled and clinically significant arrhythmias; and heart failure of Class II or higher (New York Heart Association \\[NYHA\\] functional class); LVEF (left ventricular ejection fraction) \\\u003C 50%;\n  2. Active or uncontrolled severe infection (≥ Grade 2 CTC AE infection);\n* Receipt of a prophylactic or attenuated vaccine within 4 weeks prior to the first dose;\n* Other factors, as determined by the investigator, that may lead to forced discontinuation of the study, such as other serious illnesses (including psychiatric disorders) requiring concomitant treatment, severe laboratory abnormalities, or family or social factors that could compromise the subject's safety.\n* If HBsAg (+) and\u002For HBcAb (+), HBV DNA must be \\\u003C 500 IU\u002FmL (if the local center's lower limit of detection is higher than 500 IU\u002FmL, the investigator may decide on enrollment based on specific circumstances) and the subject must continue to receive effective anti-HBV therapy during the study, or must have already started treatment with entecavir or tenofovir prior to study drug administration;\n* If HCV antibodies are positive, HCV-RNA testing must be performed; subjects with HCV-RNA \\> 10³ copies\u002FmL must be excluded;\n* HIV-positive.",{"count":428,"type":21},200,[86],"This is a prospective, single-center, randomized phase 2 study of adebrelimab plus full-course neoadjuvant therapy in resectable locally advanced esophageal squamous cell carcinoma. Patients achieving clinical complete response (cCR) after neoadjuvant treatment will be randomized 1:1 to watchful waiting with 2 cycles consolidation chemo-Immunotherapy or standard surgery. Primary endpoint is 2-year DFS. Secondary endpoints include OS, pCR\u002FMPR, R0 resection rate, safety, and quality of life.",[432],"ESCC","2026-05-07",{"date":367,"type":32},{"date":151,"type":21},{"date":437,"type":21},"2028-12-31",{"name":231,"class":39},{"id":440,"slug":441,"hasResults":12,"nctId":442,"briefTitle":443,"officialTitle":444,"acronym":4,"eligibilityCriteria":445,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":51,"phases":448,"briefSummary":449,"conditions":450,"keywords":459,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":130},"100574403","phase-2-total-neoadjuvant-therapy-and-organ-preservation-versus-surgery-for-rectal-cancer-100574403","NCT06758830","Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.","Total Neoadjuvant Therapy for Rectal Cancer - a New Standard of Care?","Part One\n\nInclusion Criteria:\n\n* Over 18 years of age.\n* Participants who agreed to participate in the study signed an informed consent form.\n* The Eastern Cooperative Oncology Group (ECOG) score ranges from 0 to 2.\n* Pathologically confirmed rectal adenocarcinoma.\n* Tumor up to 10 cm from the anus.\n* Magnetic resonance imaging (MRI) of the pelvis and computed tomography (CT) of the thorax and abdomen were performed to confirm the diagnosis.\n* cT1N1, T2-T3 N0 - 1, M0, MRF -, EMVI -.\n* Normal bone marrow function: blood leucocytes \\> 3.5 × 10⁹\u002Fl, neutrophils \\> 1.5 × 10⁹\u002Fl, platelets \\> 100 × 10⁹\u002Fl.\n* Normal renal function: creatinine within 1,5 × normal.\n* Normal liver function: blood bilirubin levels within 1,5 times normal, AST, ALT levels within 2,5 times the upper limit.\n\nExclusion Criteria:\n\n* Prior ST or Ch.\n* Participants who are not eligible for pelvic MRI.\n* Participants who have had a malignancy in the last 5 years, except for treatment for basal cell or squamous cell skin cancer or in situ cervical cancer.\n* ECOG status ≥ 3.\n* Distant metastases detected.\n* Participants with uncontrolled therapeutic or psychiatric conditions.\n* Infectious diseases requiring antibiotic treatment.\n\nPart Two\n\nInclusion Criteria:\n\n* Over 18 years of age.\n* Participants who agreed to participate in the study signed an informed consent form.\n* ECOG score between 0 and 2.\n* Pathological confirmed rectal adenocarcinoma.\n* Stage I to III rectal cancer confirmed.\n* The tumor is localized up to 12 cm from the anus.\n* Participants who refused to participate in the first part of the study or did not meet the inclusion criteria for the first part.\n* Participants have received preoperative CRT or TNT or are in the planning stages of neoadjuvant treatment.\n\nExclusion Criteria:\n\n* New cancer two years after CRT.\n* Stage IV cancer before treatment.\n* Participants refusing to participate in the study or unable to sign the informed consent.",{"count":447,"type":21},400,[86,53],"This study hypothesizes that approximately 50% of rectal cancer patients can preserve their rectum using a watch-and-wait strategy if they achieve a complete or near-complete clinical response to total neoadjuvant therapy (TNT). The objective is to determine whether the complications, quality of life, and survival rates of rectal cancer patients who have achieved a complete or near-complete clinical response to TNT, followed by a watch-and-wait approach, are comparable to those of patients who undergo surgery first. Additionally, the study aims to identify potential prognostic and predictive markers for rectal cancer and examine survival rates and factors influencing responses to chemoradiotherapy (CRT) or TNT.\n\nThe study is divided into two parts:\n\n\\*\\*Part One:\\*\\* Participants with cT1N1, T2-T3 N0-1 rectal cancer, MRF-, and EMVI-, with surgery as one of the possible first-line treatment options, will be randomized into two groups. The experimental group will consist of participants receiving TNT, including CRT and consolidation chemotherapy (Ch). If these participants achieve a complete or near-complete clinical response, they will be observed using a watch-and-wait strategy, which is a non-operative approach. The control group will consist of participants who undergo surgical treatment initially.\n\n\\*\\*Part Two:\\*\\* All participants with rectal cancer who have received CRT or TNT will be included. Additionally, participants diagnosed with rectal cancer who are scheduled for CRT or TNT but declined to participate in Part One or do not meet the inclusion criteria will also be included.",[451,452,250,119,118,453,454,455,456,457,458],"Rectal Cancer","Total Neoadjuvant Treatment","Organ Preservation","Radiotherapy Side Effect","Chemotherapy Side Effects","Chemoradiotherapy","Low Anterior Resection Syndrome","Quality of Life",[460,452,91,119,118,456,453,454,461,462,463,464,457],"Rectal cancer","Chemotherapy side effects","Quality of Lifte","Fatigue","Postoperative complications","2026-05-06",{"date":410,"type":32},{"date":468,"type":32},"2025-01-06",{"date":470,"type":21},"2029-12-27",{"name":472,"class":39},"National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos",{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":51,"phases":483,"briefSummary":484,"conditions":485,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":40},"100592962","phase-2-timing-of-minimally-invasive-local-treatment-after-first-line-systemic-therapy-in-oligometastatic-esophageal-or-gastric-adenocarcinoma-100592962","NCT07000253","Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma","Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma: A Randomized Prospective Clinical Study (OMEC-5)","OMEC-5","Inclusion Criteria:\n\n* Age ≥18 years\n* Ability to provide written informed consent\n* Histologically confirmed esophageal, gastric or gastroesophageal junction tumor with oligometastatic (M1) disease defined according to the OMEC consensus statement:\n\n  * One organ with ≤3 metastases or 1 involved extra-regional lymph node station (based on the TNM 8 classification)\n  * ≤3 unilobar liver metastases or ≤2 bilobar liver metastases\n  * ≤ 3 unilateral lung metastases\n  * Unilateral adrenal gland involvement\n  * Metastasis confined to 1 bone structure or 1 soft tissue compartment\n* Synchronous oligometastatic disease with a resectable primary tumor or metachronous oligometastatic disease (in the event of a locoregional recurrence this should be resectable)\n* Metastases should be deemed amenable by the international multidisciplinary expert team for radical local treatment\n* WHO performance status 0-2\n* Indication for checkpoint inhibition and\u002For targeted therapy\n\n  * PD-L1 with a CPS of 1 or higher as per local clinical practice for immunotherapy use\n  * HER2 overexpression as per local clinical practice for trastuzumab use\n  * Claudin 18.2 overexpression as per local clinical practice for zolbetuximab use.\n  * Any other biomarker that allows targeted therapy in first line approved by EMA\n* No prior systemic therapy for metastatic disease\n* CT-scan ≤8 weeks prior to inclusion\n* Ability to undergo local treatment and start systemic treatment beyond 18 weeks of total systemic treatment.\n\nExclusion Criteria:\n\n* Squamous cell carcinoma\n* Brain metastases\n* Peritoneal or pleural carcinomatosis\n* Patients with MSI dMMR\n* Uncontrolled immunodeficiency (e.g. AIDS)\n* Peripheral neuropathy \\>CTCAE grade 1, precluding start of full dose oxaliplatin treatment\n* Both organ metastasis and extra-regional lymph node metastasis\n* Conditions precluding local treatment or systemic therapy for oligometastatic disease:\n\n  * Serious medical comorbidities precluding local treatment (e.g., interstitial lung disease in patients with pulmonary metastasis)\n  * Clinical or radiological evidence of spinal cord compression or epidural tumor within 2 mm of the spinal cord\n  * Simultaneous other malignancy or previous other malignancy with a disease-free period of \\\u003C5 years, except adequately treated non-melanoma skin cancer or in-situ cancers\n  * Uncontrolled (bacterial) infections\n  * Significant concomitant diseases preventing the safe administration of study drugs or likely to interfere with study assessments\n  * Uncontrolled angina pectoris, cardiac failure or clinically significant arrhythmias\n  * Continuous use of immunosuppressive agents equivalent to \\>10 mg daily prednisone\n  * Concurrent use of the antiviral agent sorivudine or chemically related analogues, such as brivudine\n  * Pregnancy or breast feeding\n  * Patients (M\u002FF) with reproductive potential not implementing adequate contraceptive measures",{"count":482,"type":21},290,[86,53],"Purpose of the Study:\n\nThis clinical study investigates whether a shorter or longer duration of systemic therapy before local treatment (surgery or radiation) results in better disease control in patients with esophageal or gastric cancer with a limited number of metastases, also known as oligometastases.\n\nBackground:\n\nIn about 25% of patients with advanced esophageal or gastric cancer, the disease spreads to only a few sites (oligometastatic disease). Prior studies suggest that local treatment after systemic therapy may extend survival in this subgroup. However, it is unclear how long systemic therapy should last before initiating local treatment. The OMEC-5 study aims to clarify this and identify potential biomarkers for treatment response.\n\nStudy Design:\n\nInitiated by Amsterdam UMC and UMCU and conducted in multiple hospitals across Europe.\n\nTotal of 414 patients to be enrolled.\n\nDuration: \\~53 months (35 months enrollment + 18 months follow-up).\n\nApproved by the medical ethics committee at Amsterdam UMC.\n\nProcedure:\n\nEligibility screening: Includes physical exam, blood tests (incl. circulating tumor cells), medical history review, and confirmation of oligometastases by an expert panel.\n\nInitial treatment: All participants receive 4 months of standard systemic therapy (chemotherapy + immunotherapy and\u002For targeted therapy depending on tumor markers like HER2 or Claudin 18.2).\n\nResponse assessment (Review 1): Imaging and\u002For laparoscopic examination.\n\nIf oligometastases persist and tumors have not progressed, participants are randomized into two groups:\n\nGroup A (longer systemic therapy): 4 more months of systemic therapy, then local treatment if disease is stable, followed by 4 months of immunotherapy ± targeted therapy.\n\nGroup B (shorter systemic therapy): Immediate local treatment followed by 4 months of systemic therapy, then reassessment and potentially 4 months of immunotherapy ± targeted therapy.\n\nFollow-up: Regular scans and quality-of-life questionnaires (5 times), and periodic blood sampling (4 times).\n\nTreatments Involved:\n\nChemotherapy: CapOx or FOLFOX\n\nImmunotherapy: nivolumab or pembrolizumab\n\nTargeted therapy: trastuzumab (HER2-positive) or zolbetuximab (Claudin 18.2-positive)\n\nPotential Benefits and Risks:\n\nPatients may benefit from better disease control and a personalized treatment strategy.\n\nKnown side effects relate to the standard treatments used (chemo, immuno, targeted therapies), and no extra medical risk is expected beyond routine care.\n\nPossible inconveniences include blood draws, scans, minor surgery (laparoscopy), and time investment.\n\nData and Sample Handling:\n\nPersonal data and tumor\u002Fblood samples are coded and securely stored.\n\nData may be used for future cancer research if the patient consents.\n\nParticipants can withdraw at any time.\n\nConfidentiality and Privacy:\n\nPatient data are kept confidential, and participants have rights to access or delete their data. Privacy measures comply with GDPR and Dutch law.\n\nCompensation and Insurance:\n\nParticipation is voluntary, with no financial compensation. Standard treatment costs are covered by healthcare insurance. No extra insurance is required, as the treatment aligns with standard care practices.",[25,486,487,488,489,490],"Gastric (Stomach) Cancer","Gastric Adenocarcinoma","Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma","Esophageal Carcinoma","Gastric (Cardia, Body) Cancer","2026-05-03",{"date":433,"type":32},{"date":494,"type":32},"2026-04-29",{"date":496,"type":21},"2034-01",{"name":498,"class":39},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":51,"phases":508,"briefSummary":509,"conditions":510,"keywords":518,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":522,"startDateStruct":523,"completionDateStruct":524,"leadSponsor":526,"locationsCount":40},"100535953","phase-2-same-in-prevention-of-oxaliplatin-associated-liver-injury-100535953","NCT06258525","SAMe in Prevention of Oxaliplatin-associated Liver Injury","A Phase II, Open-Label Trial of S-Adenosylmethionine (SAMe) in Prevention of Oxaliplatin Associated Liver Injury","Inclusion Criteria:\n\n* Stage IV patients with resectable liver predominant metastatic colorectal cancer (new diagnosis or recurrent) referred to Cedars Sinai Medical Center for oxaliplatin based systemic therapy.\n* Age ≥ 18 years.\n* Patients who are planning to undergo liver resection following oxaliplatin based chemotherapy treatment.\n* ECOG Performance Status 0-2 or Karnofsky Performance Status (KPS) ≥ 60%.\n* Demonstrate adequate organ and marrow function (within 28 days of study treatment initiation)\n* Female subjects of childbearing potential should have a negative urine or serum pregnancy within 14 days prior to receiving the first dose of study medication for eligibility verification purposes. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* Female subjects of childbearing potential should be willing to use adequate methods of birth control (hormonal or barrier method of birth control) or be surgically sterile or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \\>1 year.\n* Male subjects should agree to use an adequate method of contraception starting with the first dose of therapy through 120 days after the last dose of therapy.\n* Subjects taking vitamin E ≥800 IU\u002Fday must be on a stable dose defined as:\n\n  1. No changes in prescribed dose within 180 days of the screening visit and\n  2. No new vitamin E-containing medications within 180 days of the screening visit or\n  3. Discontinuation of vitamin E ≥800 IU\u002Fday for at least 180 days prior to the screening visit.\n* Subjects taking anti-diabetic medications must be on a stable dose for at least 90 days prior to the date of the screening visit.\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study\n\nExclusion Criteria:\n\n* Currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment.\n* No other anti-cancer therapy (chemotherapy, hormonal therapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) or investigational agent may be used from 28 days prior to registration and until the end-of-study visit.\n* Has previously received chemotherapy for metastatic disease (neoadjuvant or adjuvant therapy is allowed as long as treatment was completed ≥6 months prior to recurrence).\n* Has pre-existing grade ≥ 3 neuropathy precluding use of oxaliplatin.\n* Has known additional malignancy that is progressing or requires active treatment.\n* Has a known hypersensitivity to any of the study supplement\u002Fdrugs (SAMe, oxaliplatin, flourouacil, folinic acid and capecitabine).\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.\n* Has any gastrointestinal disorder (e.g., bowel obstruction) or neurologic condition (e.g., oropharyngeal dysphagia) that may result in impairment of oral intake, inability to swallow the oral supplement, and\u002For impairment of absorption of study drug in the opinion of the treating investigator.\n* Has previous clinical diagnosis of cirrhosis, has had known history of Hep A\u002FB\u002FC or nonalcoholic fatty liver disease (NAFLD), liver transplantation, or any other cause for decompensated liver disease.\n* Known human immunodeficiency virus (HIV) infection.\n* Any of the following within 6 months prior to the screening visit: unstable cardiovascular disease, myocardial infarction, coronary artery bypass surgery, coronary angioplasty, transient ischemic attack, or cerebrovascular accident.\n* Any other condition that, in the investigator's opinion, would impede competence or compliance or delay completion of the study.\n* History of Parkinson's disease or bipolar disorder.\n\nPatients taking the following prohibited medications:\n\n* Olanzapine\n* MAO inhibiters, including:\n\n  * Isocarboxazid\n  * Linezolid\n  * Methylene blue injection\n  * Phenelzine\n  * Rasagiline\n  * Selegiline\n  * Tranylcypromine\n  * Any other MAO inhibitors The above prohibited medications cannot be taken -14 days prior to Day 0 and during study treatment.. Patients currently on or plan to be prescribed anti-psychotic medications not listed above may be excluded at the discretion of the Investigator. - Active infection as evidenced by positive urine culture, blood culture, or pneumonia.",{"count":507,"type":21},30,[86],"This is an open-label, phase II study that may provide evidence that taking S-adenosylmethionine (SAMe) supplementation prevents oxaliplatin, a type of chemotherapy drug, associated liver toxicity in patients with resectable colorectal liver metastases. Resectable means that it is able to removed with surgery. Patients will take two SAMe tablets in the morning and one tablet in the evening for 3-6 months (about 6-8 cycles of chemotherapy) in addition to oxaliplatin based chemotherapy followed by surgical removal of the colorectal liver metastases.",[511,512,513,514,515,516,517],"Colorectal Cancer","Liver Metastases","Liver Metastasis Colon Cancer","Liver Injury","Sinusoidal Obstruction Syndrome","5-Fluorouracil Toxicity","Liver Toxicity, Chemically-Induced",[519,520,521],"S-adenosylmethionine","Oxaliplatin","Stage IV colorectal cancer",{"date":465,"type":32},{"date":68,"type":21},{"date":525,"type":21},"2028-08",{"name":527,"class":39},"Cedars-Sinai Medical Center",{"id":529,"slug":530,"hasResults":12,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":82,"enrollmentInfo":535,"targetDuration":4,"studyType":51,"phases":537,"briefSummary":538,"conditions":539,"keywords":541,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":545,"lastUpdatePostDateStruct":546,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":130},"100633266","phase-3-becotatug-vedotin-mrg003-in-combination-with-pd-1-inhibitor-versus-pd-1-inhibitor-for-the-treatment-of-egfr-positive-cps1-resectable-locally-advanced-head-and-neck-squamous-cell-carcinoma-100633266","NCT07524452","Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","A Phase III Study of Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma： a Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form;\n2. Untreated, histologically confirmed head and neck squamous cell carcinoma (oral cavity, oropharynx, hypopharynx, or larynx), EGFR-positive, CPS ≥ 1, with clinical stage (AJCC 8th edition): p16-positive oropharynx: Stage III (T4N0-2M0); p16-negative oropharynx: Stage III or IVA; larynx\u002Fhypopharynx\u002Foral cavity: Stage III or IVA;\n3. Eligible for curative-intent surgery as determined by the surgeon;\n4. Age: 18 to 75 years;\n5. ECOG performance status 0-1;\n6. Life expectancy greater than 6 months;\n7. At least one measurable lesion per RECIST 1.1;\n8. Adequate organ function, based on meeting all of the following criteria (no receipt of blood components or hematopoietic growth factors within 14 days prior to testing): hemoglobin ≥ 90 g\u002FL; absolute neutrophil count ≥ 1.5 × 10⁹\u002FL; platelet count ≥ 100 × 10⁹\u002FL; serum albumin ≥ 28 g\u002FL; total bilirubin ≤ 1.5 × upper limit of normal (ULN); ALT and AST ≤ 2.5 × ULN; serum creatinine ≤ 1.5 × ULN, with creatinine clearance ≥ 50 mL\u002Fmin; activated partial thromboplastin time and international normalized ratio (INR) ≤ 1.5 × ULN (patients receiving a stable dose of anticoagulant therapy, such as low molecular weight heparin or warfarin, may be enrolled if INR is within the expected therapeutic range for the anticoagulant). Thyroid-stimulating hormone (TSH) ≤ ULN; if abnormal, T3 and T4 levels should be assessed, and patients with normal T3 and T4 levels may be enrolled;\n9. Baseline left ventricular ejection fraction (LVEF) ≥ 50% as measured by multigated acquisition (MUGA) scan or echocardiography (ECHO);\n10. Women of childbearing potential must agree to use contraception (e.g., intrauterine device, contraceptive pill, or condom) during the treatment period and for 3 months after the last dose;\n11. Good compliance.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women.\n2. History of allergy to PD-1 inhibitors.\n3. History of other malignancies within the past 5 years or at enrollment, with the exception of cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and thyroid papillary tumors.\n4. Residual toxicity from prior anti-tumor therapy (including immunotherapy, targeted therapy, chemotherapy, or radiotherapy, etc.) other than alopecia, fatigue, and grade 2 hypothyroidism, or clinically significant laboratory abnormalities greater than grade 1 (CTCAE v5.0).\n5. Uncontrolled cardiac conditions or diseases, such as: ① NYHA Class II or greater heart failure, ② unstable angina, ③ myocardial infarction within 1 year, and ④ patients with clinically significant ventricular arrhythmias requiring intervention.\n6. Grade ≥ 2 peripheral neuropathy (per CTCAE v5.0).\n7. Pulmonary embolism or deep vein thrombosis within 3 months prior to enrollment (excluding catheter-related thrombosis from infusion ports or PICC lines).\n8. Active bleeding, history of coagulation disorders, or patients receiving coumarin anticoagulant therapy.\n9. Known hypersensitivity to any component or excipient of vibecotamab (citric acid monohydrate, sodium citrate dihydrate, trehalose dihydrate, sodium chloride, and polysorbate 80), or known grade ≥ 3 hypersensitivity reaction to other prior anti-EGFR agents (including investigational drugs) or other monoclonal antibodies.\n10. Receipt of any of the following treatments:\n\n    ① Any investigational drug prior to the first dose of the current study drug.\n\n    ② Concurrent participation in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period.\n\n    ③ Use of systemic corticosteroids (more than 10 mg of prednisone or equivalent per day) or other immunosuppressive agents within 2 weeks prior to the first dose of study drug, except for the use of corticosteroids for localized inflammation, prevention of allergies, or nausea and vomiting. In the absence of active autoimmune disease, inhaled or topical steroids and adrenal corticosteroid replacement doses greater than 10 mg prednisone equivalent per day are permitted.\n\n    ④ Administration of live vaccines within 4 weeks prior to the first dose of study drug.\n\n    ⑤ Major surgery or severe trauma within 4 weeks prior to the first dose of study drug.\n11. Severe infection (greater than grade 2 per CTCAE), such as severe pneumonia requiring hospitalization, bacteremia, or infectious complications, occurring within 4 weeks prior to the first dose of study drug; baseline chest imaging indicating active pulmonary inflammation or signs and symptoms of infection within 2 weeks prior to the first dose of study drug, or indicating the need for oral or intravenous antibiotic therapy (excluding prophylactic antibiotic use).\n12. History of or concurrent severe chronic obstructive pulmonary disease with respiratory failure, severe pulmonary insufficiency, symptomatic bronchospasm, etc.\n13. History of active autoimmune diseases or syndromes (including but not limited to interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism). Patients with vitiligo that did not require any intervention in adulthood, or childhood asthma\u002Fallergy that has resolved, are not excluded.\n14. History of immunodeficiency, including HIV-positive status or other acquired\u002Fcongenital immunodeficiency diseases, or history of organ transplantation or bone marrow transplantation.\n15. Patients with active tuberculosis infection by history or CT findings, or history of active tuberculosis infection within 1 year prior to enrollment, or history of active tuberculosis infection more than 1 year prior without receiving formal treatment.\n16. Active hepatitis B (HBV DNA ≥ 2,000 IU\u002FmL or 10,000 copies\u002FmL) or hepatitis C (positive HCV antibody test with HCV RNA above the lower limit of detection).\n17. Uncontrolled pleural, peritoneal, pelvic, or pericardial effusion requiring drainage ≥ 1 time per month.\n18. Known history of substance abuse, alcoholism, or drug use.\n19. Inappropriate for inclusion based on the investigator's judgment.",{"count":536,"type":21},430,[53],"This study is a randomized, open-label, multicenter phase III trial designed to systematically evaluate the efficacy and safety of perioperative neoadjuvant and adjuvant therapy with Becotatug vedotin in combination with PD-1 inhibitor versus PD-1 inhibitor alone in patients with EGFR-positive, CPS ≥ 1 resectable locally advanced head and neck squamous cell carcinoma .",[540],"Locally Advanced Head and Neck Squamous Cell Carcinoma",[542,543,544],"Resectabl locally advanced head and neck squamous cell carcinoma","Becotatug Vedotin","perioperative neoadjuvant and adjuvant therapy","2026-04-06",{"date":547,"type":32},"2026-04-13",{"date":549,"type":32},"2026-02-06",{"date":551,"type":21},"2032-02-28",{"name":553,"class":39},"Ming-Yuan Chen",{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":560,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":562,"targetDuration":4,"studyType":51,"phases":564,"briefSummary":565,"conditions":566,"keywords":569,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":582},"100524851","trial-comparing-systemic-therapy-alone-and-with-local-ablative-treatment-for-stage-iv-nscl-cancer-patients-100524851","NCT06114108","Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients","Phase III Randomized Controlled Trial Comparing Maintenance Systemic Therapy Alone With Systemic Therapy Plus Local Ablative Treatment for Patients With Advanced Stage IV Non-small Cell Lung Cancer","salVage","Inclusion Criteria:\n\nPatients fulfilling all of the following inclusion criteria at screening may be enrolled in the trial.\n\n* The inclusion criteria are irrespective from the tumor burden at the time of primary diagnosis before initiation of first line systemic therapy. Treatment of brain metastases upfront or after an induction phase of standard systemic therapy is done according to the standard practice of the treating center.\n* Adults (18 years or older)\n* Tissue confirmed, pre-treatment clinical stage IV NSCLC\n* ECOG performance status ≤ 1\n* Patients responding after 3 cycles (4th bridging cycle up until randomization is allowed) or 3 months of first line SoC systemic therapy with PR or SD in restaging imaging, and presenting with (induced) oligometastatic or oligopersistent NSCLC defined as a maximum of 5 residual extracranial, distant metastases\n* Patients may have up to 5 cranial metastases in addition to the oligoresidual extracranial metastases as long as they are amenable for radiotherapy or surgery.\n* The primary tumor and all oligopersistent metastases must be amenable for radical LAT (surgery or radiotherapy)\n* Patients of reproductive age agree to use double contraception during the study\n* Patient is able to understand trial procedures and is able\u002Fwilling to adhere to trial procedures as confirmed by signature\n\nExclusion Criteria:\n\nThe presence of any one of the following exclusion criteria at screening will lead to exclusion of the participant:\n\n* Serious concomitant disorder that would compromise patient safety during LAT\n* Unresolved complications from initial systemic anticancer treatment, higher than CTCAE grade 2\n* Metastatic locations such as malignant ascites, malignant pleural or malignant pericardial effusion, diffuse lymphangiosis of skin or lung, diffuse bone marrow metastasis, abdominal masses\u002Fabdominal organomegaly, identified by physical exam that is not measurable by reproducible imaging techniques, leptomeningeal carcinomatosis\n* Women who are pregnant or breast feeding\n* Patient is currently involved in a trial that either does not permit participation in other trials or would result in excessive patient burden if another trial were joined. In such cases, the co-investigators' team and the Patient Advisory Board will decide on participation on an individual basis.",{"count":563,"type":21},128,[385],"Unfortunately, most patients are already at a very advanced stage when they are diagnosed with lung cancer, i.e. the cancer has already spread outside the lungs forming metastases. The current standard of care therapy at this advanced stage of lung cancer includes systemic anti-cancer therapy such as chemotherapy, immunotherapy to boost the body's immune response, or targeted therapy that directly hinders tumor growth. In this study, the aim is to find out whether it is better if, after a good response to the standard therapy, the remains of main tumor and the metastases are additionally treated by surgery and\u002For radiation.",[567,568],"Non-small Cell Lung Cancer (NSCLC)","Stage IV",[570,571,572],"Non-small cell lung cancer (NSCLC)","Local consolidative treatment (LAT)","patient-reported outcome measures (PROMs)","2026-03-27",{"date":575,"type":32},"2026-04-02",{"date":577,"type":32},"2023-12-21",{"date":579,"type":21},"2028-03-01",{"name":581,"class":39},"Swiss Cancer Institute",7,{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":590,"enrollmentInfo":591,"targetDuration":4,"studyType":51,"phases":593,"briefSummary":594,"conditions":595,"keywords":596,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":130},"100538658","effect-of-limb-length-ratio-on-roux-en-y-gastric-bypass-outcomes-climb-ii-study-100538658","NCT06293703","Effect of Limb Length Ratio on Roux-en-Y Gastric Bypass Outcomes (CLIMB II Study)","CLIMBII","Inclusion Criteria:\n\n* morbidly obese patients (defined by BMI between 40 and 60).\n* Patient who understands and accepts the need for a long-term follow-up.\n* Patient who agrees to be included in the study\n\nExclusion Criteria:\n\n* individuals unable to understand and sign a written consent form\n* patients with history of previous bariatric surgery procedures\n* presence of a severe and evolutive life threatening pathology unrelated to obesity\n* previous gastric or small bowel resection\n* active cancer\n* pregnancy or desired to be pregnant during the study\n* mentally unbalanced patients under supervision or guardianship, patient unable to give consent","70 Years",{"count":592,"type":21},262,[385],"The investigators propose a randomized controlled trial comparing BP and roux limb lengths measuring 30 and 15% respectively of patient's total small bowel length versus current standard practice using fixed lengths. The findings would provide further insight into feasibility of standardizing RYGB limb lengths and optimizing resultant weight loss and metabolic effects. The investigators hypothesize RYGB with ratio-adjusted limb lengths (aRYGB) will result in higher total weight loss and resolution of metabolic syndrome comorbidities, including diabetes, hyperlipidemia, and hypertension compared to standard fixed-length RYGB (sRYGB). The study will also utilize the Short Form Rand 36-Item Health Survey (SF36) to determine differences in postoperative quality of life metrics.",[299],[597,598,599],"Bariatric surgery","Roux-n-Y gastric bypass","gastric bypass","2026-03-18",{"date":602,"type":32},"2026-03-20",{"date":604,"type":32},"2024-01-12",{"date":606,"type":21},"2030-12-11",{"name":608,"class":39},"Salvador Navarrete",{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":615,"eligibilityCriteria":616,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":139,"enrollmentInfo":617,"targetDuration":4,"studyType":51,"phases":619,"briefSummary":620,"conditions":621,"keywords":624,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":4},"100629269","phase-2-phase-ii-neoadjuvant-study-of-garsorasib-followed-by-ivonescimab-plus-chemotherapy-in-resectable-stage-iia-iiib-kras-g12c-mutant-nsclc-given-study-100629269","NCT07472478","Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)","An Exploratory Phase II Clinical Study Protocol of Perioperative Treatment With Glesorasib Sequentially Combined With Ivonescimab and Chemotherapy for Resectable, Stage IB-IIIB, KRAS G12C-Mutant NSCLC","GIVEN","Inclusion Criteria:\n\n1. Age Range: Males or females aged 18 years or older.\n2. Diagnosis and Stage: Patients with histologically or cytologically confirmed resectable IB-IIIB NSCLC, staged according to the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology, 9th Edition.\n3. Informed Consent: Patients must voluntarily participate in the study, provide written informed consent, and be willing to comply with follow-up procedures.\n4. Prior Therapy: No prior systemic therapy for locally advanced or metastatic NSCLC (including adjuvant chemo\u002Fradiotherapy, neoadjuvant chemo\u002Fradiotherapy, definitive chemoradiotherapy, chemotherapy, radiotherapy, immune checkpoint inhibitors, targeted therapy, or anti-angiogenic therapy for locally advanced disease).\n5. Mutation Status: KRAS G12C mutation positivity must be confirmed by next-generation sequencing (NGS) or polymerase chain reaction (PCR) testing.\n6. Measurable Disease: At least one measurable target lesion as per RECIST v1.1. Lesions previously treated with radiotherapy or other local-regional therapies cannot be considered target lesions unless clear progression has been documented post-radiotherapy. At baseline, the lesion must be ≥10mm in the longest diameter (≥15mm in short axis for lymph nodes) on CT or MRI and be suitable for accurate repeated measurement per RECIST v1.1.\n7. Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n8. Adequate Organ Function: Must meet the following criteria within 14 days prior to relevant tests, without transfusion or use of hematopoietic growth factors:\n\n   1. Platelets (PLT) ≥90 × 10\\^9\u002FL\n   2. Hemoglobin (HGB) ≥90 g\u002FL\n   3. Absolute Neutrophil Count (ANC) ≥1.5 × 10\\^9\u002FL\n   4. Serum creatinine ≤1.5 × ULN or Creatinine Clearance (CrCl) ≥50 mL\u002Fmin (calculated using the Cockcroft-Gault formula)\n   5. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) ≤2.5 × ULN (≤5 × ULN if liver metastases are present)\n   6. Total Bilirubin (TBIL) ≤1.5 × ULN (≤3 × ULN for patients with Gilbert's syndrome)\n   7. International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 × ULN, and Activated Partial Thromboplastin Time (APTT) ≤1.5 × ULN, or patients assessed by the investigator as having controlled bleeding tendency.\n   8. Urinalysis showing urine protein \\\u003C2+ or 24-hour urinary protein quantification \\\u003C1g.\n9. Life Expectancy: Expected survival time ≥3 months.\n10. Contraception: Fertile female subjects must agree to use effective contraception (e.g., IUD, oral contraceptives, condoms) during the study and for 6 months after study completion; have a negative serum pregnancy test within 7 days before enrollment; and must not be breastfeeding. Male subjects must agree to use effective contraception during the study and for 6 months after study completion.\n\nExclusion Criteria:\n\n1. Prior Anti-Tumor Therapy:\n\n   1. Previous receipt of any anti-tumor therapy for lung cancer (including adjuvant chemoradiotherapy, neoadjuvant chemoradiotherapy, chemotherapy, radiotherapy, immune checkpoint inhibitors, targeted therapy, anti-angiogenic therapy, etc.).\n   2. Treatment with any other investigational drug within 28 days prior to the first dose in this study.\n   3. Treatment within 2 weeks prior to the first dose with NMPA-approved Chinese patent medicines explicitly indicated for anti-tumor purposes in their drug说明书 (e.g., Compound Banmao Capsules, Kang'ai Injection, Kanglaite Capsules\u002FInjection, Aidi Injection, Yadanzi Oil Injection\u002FCapsules, Xiaoaiping Tablets\u002FInjection, Huachansu Capsules, etc.).\n2. Recent Surgery: Any surgery within 4 weeks prior to screening examinations.\n3. Concurrent Primary Malignancy: Patients with a concurrent primary malignancy (except for adequately treated basal cell carcinoma of the skin, carcinoma in situ of the cervix, etc.).\n4. Abnormal Organ Function: Meeting any of the following at screening:\n\n   1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 1.5 times the upper limit of normal (ULN).\n   2. Creatinine clearance rate (CrCl) \\> ULN.\n5. Hematological Abnormalities: Total white blood cell (WBC) count \\> 10.0 × 10\\^9\u002FL or \\\u003C 1.0 × 10\\^9\u002FL at screening.\n6. Significant Comorbidities: History of immunodeficiency diseases (e.g., HIV), other active cancers or malignancy history, autoimmune diseases, severe cardiovascular or cerebrovascular diseases, or any other diseases that may significantly reduce life expectancy.\n7. Conditions Affecting Compliance: Any history of conditions that may affect protocol compliance (e.g., severe psychiatric disorders, cognitive dysfunction, drug abuse or addiction).\n8. Pregnancy, Lactation, and Contraception: Pregnant or lactating women, or subjects of childbearing potential unwilling or unable to use effective contraception.\n9. Allergy: Known allergy to any component of the study drug(s).\n10. Recent Trial Participation: Participation in any drug clinical trial within 6 months prior to screening.\n11. Investigator's Discretion: Any condition considered by the investigator as unsuitable for study participation.\n12. Other Driver Mutations: Non-small cell lung cancer with other standard-therapy-eligible driver gene mutations (e.g., EGFR, ALK, BRAF V600E, HER-2, MET Exon 14, ROS1, RET, or NTRK1\u002F2\u002F3).\n13. Central Nervous System (CNS) Metastases:\n\n    1. Symptomatic or progressive CNS metastases or carcinomatous meningitis.\n    2. Subjects with a history of brain metastases may be considered if they are clinically stable: no neurological symptoms, no corticosteroid treatment required, no indication for radiotherapy, and the largest diameter of the largest metastatic lesion on recent imaging is ≤ 1.5 cm.\n    3. Asymptomatic CNS metastases newly discovered during screening are allowed.\n    4. Subjects with a history of asymptomatic CNS metastases require confirmation of no progression via imaging scans performed at least 2 weeks apart.\n    5. Subjects with symptomatic CNS metastases may be considered if clinically stable after radiotherapy and\u002For surgery.\n    6. Subjects who underwent surgery for CNS metastases must have an interval of at least 4 weeks before the first study dose.\n    7. Asymptomatic subjects after CNS radiotherapy must have discontinued corticosteroids for at least 2 weeks prior to the first dose.\n14. Cardiovascular Disease: Any of the following:\n\n    1. Congestive heart failure of New York Heart Association Class II or above.\n    2. Severe arrhythmia requiring medication.\n    3. Acute myocardial infarction, severe or unstable angina, coronary or peripheral artery bypass graft within 6 months prior to enrollment.\n    4. Left ventricular ejection fraction (LVEF) \\\u003C 50%.\n    5. Prolonged QTcF interval ( \\> 470 ms for females, \\> 450 ms for males) or risk factors for Torsades de Pointes.\n    6. Uncontrolled hypertension (systolic BP ≥ 150 mmHg and\u002For diastolic BP ≥ 100 mmHg after antihypertensive therapy).\n15. Thromboembolic Events: Arterial\u002Fvenous thrombotic events within 6 months, hypertensive crisis, or hypertensive encephalopathy.\n16. History of Epilepsy: Previous history of epilepsy.\n17. Superior Vena Cava Syndrome: Presence of superior vena cava syndrome.\n18. Pulmonary Disease: Active non-infectious interstitial lung disease, radiation pneumonitis, etc., active tuberculosis, pneumoconiosis, ≥ Grade 2 other pneumonias, or severely impaired pulmonary function at screening.\n19. Severe Bone Lesions: Existing or potential severe bone damage from metastases, or uncontrolled bone pain.\n20. Active Infection: Active or uncontrolled severe infection, or unexplained fever \\> 38.5°C.\n21. Third-Space Fluid: Poorly controlled or drainage-requiring pleural effusion, ascites, or pericardial effusion. Subjects stabilized after treatment may be enrolled.\n22. Tumor Invading Major Vessels: Imaging shows tumor invading or with unclear boundaries to major blood vessels.\n23. Bleeding Risk: Evidence or history of bleeding tendency within 2 months before the first dose; history of hemoptysis, or unhealed wounds\u002Fulcers\u002Ffractures within 2 weeks before the first dose.\n24. Gastrointestinal Diseases: Known GI impairment or diseases significantly affecting drug absorption\u002Fmetabolism, or major GI surgery affecting absorption.\n25. Recent Live Vaccination: Administration of a live attenuated vaccine within 4 weeks before the first dose.\n26. Severe Hypersensitivity to mAbs: History of severe hypersensitivity reaction to other monoclonal antibodies.\n27. Autoimmune Disease: Active autoimmune disease requiring systemic treatment within 2 years before the first dose.\n28. Immunosuppressive Therapy: Receiving systemic corticosteroids or other immunosuppressive therapy.\n29. Viral Infections: Positive HIV antibody, or active viral hepatitis.\n\n    1. Active Hepatitis B or active Hepatitis C.\n    2. Carriers require antiviral therapy and monitoring during the study.\n30. Active Syphilis.\n31. Renal Failure: Requiring hemodialysis or peritoneal dialysis.\n32. Poorly Controlled Diabetes: Fasting blood glucose \\> 10 mmol\u002FL.\n33. Organ Transplant: History of or planned organ transplantation.\n34. Recent Major Surgery\u002FTrauma: Major surgery or significant trauma within 4 weeks before the first dose.\n35. Recent Radiotherapy: Palliative radiotherapy within 2 weeks before the first dose.\n36. Residual Toxicity from Prior Therapy: Toxicities from previous anti-cancer therapy not recovered to Grade ≤1.\n37. Other: Any other clinically significant abnormality or disease deemed by the investigator to pose risk or interfere with the study.",{"count":618,"type":21},32,[86],"This study is a multicenter, prospective, open-label clinical trial. It enrolls previously untreated patients with resectable stage IB-IIIB KRAS G12C mutation-positive NSCLC to evaluate the efficacy and safety of glesorasib sequentially combined with ivonescimab and chemotherapy as perioperative treatment for this patient population.",[622,623],"Lung Cancer (NSCLC)","KRAS G12C Lung Cancer",[625,626,627],"lung cancer","KRAS","KRAS G12C","2026-03-13",{"date":630,"type":32},"2026-03-16",{"date":632,"type":21},"2026-03-15",{"date":634,"type":21},"2028-03-31",{"name":636,"class":39},"Guangdong Provincial People's Hospital",{"id":638,"slug":639,"hasResults":12,"nctId":640,"briefTitle":641,"officialTitle":642,"acronym":4,"eligibilityCriteria":643,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":644,"enrollmentInfo":645,"targetDuration":4,"studyType":51,"phases":647,"briefSummary":648,"conditions":649,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":651,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":656,"locationsCount":130},"100512295","phase-2-ivim--olink-in-sarcoma-100512295","NCT05950594","IVIM & OLINK in Sarcoma","Prospective Study of Image and Blood-derived Biomarkers to Predict Metastasis in Soft-tissue Sarcomas","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Ability to understand and the willingness to sign a written informed consent document\n* Grade 2 or 3 soft tissue sarcoma greater than 5 cm in largest dimension\n\nExclusion Criteria:\n\n* Contraindication to MRI scan as per current institutional guidelines (for patients requiring MRI)","100 Years",{"count":646,"type":21},145,[86],"The hypoxia \\> metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling stratification for personalized treatments at the time of diagnostic (MR) imaging, without adding an excessive burden to the patient or clinical workflow (typical DWI\u002FIVIM sequences can be acquired acquired in approximately 5 minutes).",[248],"2026-03-11",{"date":630,"type":32},{"date":653,"type":32},"2024-03-05",{"date":655,"type":21},"2027-11-30",{"name":657,"class":39},"University Health Network, Toronto",{"id":659,"slug":660,"hasResults":12,"nctId":661,"briefTitle":662,"officialTitle":662,"acronym":4,"eligibilityCriteria":663,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":664,"targetDuration":4,"studyType":51,"phases":666,"briefSummary":667,"conditions":668,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":670,"lastUpdatePostDateStruct":671,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":130},"100597018","phase-2-laser-interstitial-thermal-therapy-litt-or-surgery-and-adjuvant-reirradiation-for-recurrent-brain-metastases-lasar-beam-100597018","NCT07053033","Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign a written informed consent document.\n* Willingness to comply with all study procedures and availability for the duration of the study.\n* Age ≥18 years. Because no dosing or adverse event data are currently available on the use of SRS2, children are excluded from this study.\n* Karnofsky performance status ≥ 60.\n* Radiographic concern for progression of a solid tumor brain metastasis that has received prior stereotactic radiosurgery ≥ 3 months prior to study enrollment.\n* Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as ≥5 mm with MRI scan.\n* Have active tumor on pathology from surgery\u002FLITT for this lesion.\n* Able to safely undergo MRI imaging.\n* Acceptable candidate for SRS2 per treating physician and multidisciplinary conference consensus.\n* Have no radiographic evidence of leptomeningeal disease on radiology report or neuro-radiologist review.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n\nExclusion Criteria:\n\n* Patients with brain metastases from hematologic malignancies due to significant differences in radiosensitivity and treatment paradigms.\n* Patients with psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because radiation has the potential for teratogenic or abortifacient effects. All female patients between the onset of menses and 55 years will receive a pregnancy test prior to SRS2 unless the patient presents with an applicable exclusionary factor which may be one of the following:\n* Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n* History of hysterectomy or bilateral salpingo-oophorectomy.\n* Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).\n* History of bilateral tubal ligation or another surgical sterilization procedure.",{"count":665,"type":21},155,[86],"standard paradigm for management of patients who present with concern for recurrence of brain metastases following initial stereotactic radiosurgery (SRS).",[669],"Brain Metastases","2026-03-05",{"date":672,"type":32},"2026-03-09",{"date":674,"type":32},"2026-01-01",{"date":676,"type":21},"2028-12-30",{"name":678,"class":39},"M.D. Anderson Cancer Center",""]